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DACLIZUMAB (DAC)+/- MYCOPHENOLATE MOFETIL (MMF) FOR
CONTROL OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN ALLOGENEIC
STEM CELL TRANSPLANT PATIENTS WITH CYCLOSPORINE (CSA) OR
TACROLIMUS (TAC) INTOLERANCE
Abhyankar, S.; McGuirk, J.; Day, S.; Barnhart, C.; Belt, R. Oncology
& Hematology Associates and Saint Luke’s Hospital, Kansas City, MO
As a standard in the prevention of GVHD, CSA or TAC thera-
py is often comprised due to toxicities including renal failure, neu-
rotoxicity, microangiopathic hemolytic anemia (MAHA), and
hemolytic uremic syndrome (HUS). From January 2000 to July
2001, 19% (7/37) of allogeneic stem cell transplant patients (pts)
became CSA (n=1) or TAC (n=6) intolerant due to HUS (n=4),
neurotoxicity (n=2), and MAHA (n=1). CSA or TAC was discon-
tinued at a median of day +91 (24-490). Upon discontinuation of
CSA or TAC, 3 pts (43%) had DAC and MMF initiated, 2 pts
(29%) had only DAC initiated, and 2 pts (29%) previously receiv-
ing DAC for treatment of GVHD had DAC continued and MMF
added for GVHD control. DAC was administered as 1mg/kg/dose
IV 1-2 times weekly. DAC continued for a median of 56 (21-163)
days and 8 (4-23) doses. MMF was administered orally as 15mg/kg
bid. MMF continued for a median of 67 (27-184+) days. Upon ini-
tiation of DAC + MMF, 4 pts (57%) had active or resolving acute
or chronic GVHD and thus, received DAC + MMF for further
GVHD control. Of these 4 pts, 3 had stabilization or resolution of
GVHD and 1 pt had progression of GVHD while on DAC +
MMF. Three pts (43%) initiated DAC +/- MMF with no evidence
of GVHD. None of these 3 pts developed GVHD while receiving
DAC +/- MMF. No pt experienced adverse effects related to
DAC. Neutropenia (n=2) and diarrhea (n=1) due to MMF
resolved with dose reductions. No pt has relapsed. Two of the 7
pts are alive. Five pts have expired due to: ﬂudarabine-associated
neurotoxicity (1), fungal infection (1), HUS (1), ARDS (1), and
chronic GVHD (1). Our experience suggests DAC plus MMF is
an effective alternative for GVHD control in patients unable to
tolerate cyclosporine or tacrolimus.
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SEVERE VENO-OCCLUSIVE DISEASE (VOD) DEVELOPING AFTER A
REDUCED INTENSITY CONDITIONING (RIC) REGIMEN FOR A
MATCHED UNRELATED DONOR (MUD) PERIPHERAL BLOOD STEM
CELL TRANSPLANT (PBSCT) FOR ACUTE LEUKEMIA
Abhyankar, S.; McGuirk, J.; Barnhart, C.; Day, S.; Belt, R. Oncology
& Hematology Associates and Saint Luke’s Hospital, Kansas City, MO
RIC regimens are used in allo-PBSCT to reduce transplant
related morbidity and mortality. VOD is a potentially fatal side
effect that can be prevented with RIC. We report a patient who
developed severe VOD after RIC for a MUD PBSCT. SK, a 39yo
diagnosed with ALL in Feb 2000, achieved remission after stan-
dard induction chemotherapy. After consolidation, she underwent
a syngeneic PBSCT with total body irradiation and cyclophos-
phamide. She relapsed one year following syngeneic PBSCT and
achieved a second complete remission after receiving 2 cycles of
hyper-CVAD. She then immediately underwent a MUD PBSCT.
Conditioning consisted of busulfan (1mg/kg q6h x 8 doses), ﬂu-
darabine (25mg/m2/day x 5 days) and horse anti-thymocyte glob-
ulin (10mg/kg/d x 4 days). Tacrolimus and methotrexate were
given for graft versus host disease (GvHD) prophylaxis. On day
+20, her creatinine increased to 2.3mg/dl. Bilirubin was elevated
by day +29 to 4.8mg/dl with development of oliguria, >5% weight
gain and mental status changes. Serum plasminogen activator
inhibitor (PAI-1) was elevated at 230IU/ml. Transjugular liver
biopsy was consistent with VOD. Dialysis was initiated for renal
failure and tacrolimus was stopped. A transjugular intra-hepatic
portocaval shunt (TIPS) was placed on day +35. By day +40 urine
output improved and bilirubin decreased to 2mg/dl. With
improvement in mentation, the patient was discharged on day +49
on daclizumab and mycophenolate for GvHD prophylaxis. She
was readmitted with persistent nausea and diagnosed with GI
GvHD on endoscopy and biopsy. Treatment with steroids was
initiated, but the patient expired on day +106 with persistent
GvHD symptoms and signiﬁcant edema and ascites. Severe VOD,
thus, can still occur with RIC regimens in high-risk patients. In
our patient, VOD occurred late, and though, hyperbilirubinemia
and mentation improved with the TIPS procedure, significant
capillary leak and ascites remained and contributed to her ultimate
demise.
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IMMUNOABLATIVE TRANSPLANTATION FOR LYMPHOID MALIGNANCIES
Briggs, A.1; Safah, H.2; List, A.1; Epner, E.1; Weiner, R.2; Rink, J.2;
Miller, A.2 1. University of Arizona, Tucson, AZ; 2. Tulane Universi-
ty, New Orleans, LA
We have treated 17 patients with an immunoablative regimen of
ﬂudarabine (30 mg/m2 x 3) and melphalan (80 mg/m2 x 2) and
allogeneic peripheral blood progenitor transplantation. GVHD
prophylaxis was cyclosporine A and short course methotrexate.
Ages ranged from 34-54 years. Fourteen had 6 antigen matched
sibling donors, 2 MUD, and one 5/6 matched sibling donor. All
patients had lymphoid malignancies including: Multiple Myeloma
(5), Waldenstroms Macroglobulinemia (1), CLL (2), Hodgkin’s
Disease (1) and NHL (8) most were heavily pre-treated. The
NHL patients included 3 with transformed disease and one each
with T-cell, Burkitt-like and Mantle Cell lymphoma. Follow-up
ranges from 31 days to two years. Three patients died within one
year of transplant of infection, GVHD or both, a fourth patient
died in CR of sepsis 18 months post-transplant. Of the remaining
13 patients, 10 have follow-up of greater than 100 days, with 7 in
CR, 1 PR, and 2 with progressive disease (HD and transformed
lymphoma). One patient with CLL is now 2 years post transplant
in CR but with cGVHD requiring treatment. Grade 2 or greater
acute GVHD occurred in 9/17. Chronic GVHD occurred in 8/12
patients evaluable at greater than 100 days. Median to recovery of
an absolute granuloyte count of 500 and a platelet count of 20,000
was 12 days for each. Four patients experienced grade 3-4
mucousitis. Six had chimerism studies performed between 3 and 6
months, all are 100% donor. Overall survival is 76% with a medi-
an follow-up of 200 days. Overall toxicity is moderate with a few
patients with moderate to severe mucositis, and/or GVHD and
rapid hematopoietic recovery. GVHD was common, and a factor
in three of four deaths. All patients who have had chimerism stud-
ies have shown 100% donor origin cells. This regimen appears
promising for patients with lymphoid malignancies.
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CHIMERISM ANALYSIS FOR NON-MYELOABLATIVE TRASPLANTATION:
EVALUATION OF ANTI-COAGULANT, TEMPERATURE AND TIME
BETWEEN SAMPLE COLLECTION AND PROCESSING ON LYMPHOID
AND MYELOID CELL ENRICHMENT
Clarke, E.1; Marciniak, R.1; Thomas, T.E.1; Eaves, A.C.1,2 1. StemCell
Technologies Inc, Vancouver, BC, Canada; 2. Terry Fox Laboratory,
Vancouver, BC, Canada
Non-myeloablative transplants have reduced the incidence of
early transplant-related mortality but have done little to alleviate
the complications of rejection and GVHD. Withdrawl of
immunosuppression or administration of DLI is generally based
on the results of chimerism analysis of puriﬁed T-cells. Previously
we reported that lymphoid (CD3+) or myeloid (CD33+) popula-
tions could be rapidly (< 1 hour) isolated (purity > 95%) directly
from heparinized whole blood using RosetteSepTM. In this study,
we evaluated the effects of anti-coagulants, storage temperature
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and time from sample collection to cell enrichment on purities
and recoveries of CD33+ and CD3+cells. The purities and recover-
ies of CD33+cells were not effected by either heparin or ACD if
samples were processed immediately (T0). Collection into ACD
and storage for 24 hours (T24) at 4oC resulted in a reduced
CD33+cell purity, while storage of ACD samples at 22oC caused
extensive myeloid cell death making isolation of CD33+cells
impossible. The enrichment and recovery of CD3+cells were not
compromised by choice of anti-coagulant at T0; however, if there
was a 24 hour delay between collection and processing, storage at
room temperature (22oC) was optimal particularly for samples col-
lected into ACD.
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ALLOGENEIC TRANSPLANTATION IN HODGKIN’S DISEASE FOR
PATIENTS WHO FAIL AUTOLOGOUS TRANSPLANTATION IS SAFE AND
EFFECTIVE
Cooney, J.P.; Stiff, P.J.; Toor, A.A.; Parthasarathy, M. University of
Loyola Medical Center, Maywood, IL
Previous attempts of allogeneic transplantation in patients
with relapsed /refractory Hodgkin’s Disease have been unsuc-
cessful due to high treatment related mortality with only 15%
long term survivors. With advances in supportive care and
GVHD prophylaxis, we re-explored this therapy in nine
patients failing autografts. Patients received BEAM (BCNU
300mg/m2, Etoposide 800mg/m2, Cytarabine 1600mg/ m2 and
Melphalan 140mg/m2) and either matched sibling peripheral
blood stem cells (5), partially matched sibling bone marrow (1)
or matched unrelated bone marrow (3). GVHD prophylaxis
was with FK-506 with planned weaning at Day + 60, and mini-
methotrexate. The median age was 36 years (range 21-49). The
median time from diagnosis was 64 months (12-172), and from
autograft was 46 months (6-143 months). At the time of trans-
plant, one patient was in complete remission, five patients were
in partial remission, three were in relapse and one patient had
primary refractory disease. All patients engrafted satisfactorily.
The 28-day mortality is 0%. At an average of 11 months (3-
18), eight patients (89%) are alive. Two patients developed
acute GVHD. All 8 patients reaching 100 days had stopped
FK-506. Four of the 8 have developed mild chronic GVHD
(one mild and transient in a patient who subsequently
relapsed). The complete response rate is 78% and partial
remission rate is 22%. Three patients have relapsed (at 2, 6 & 8
months) and two have received donor lymphocyte infusions.
One patient died at 4 months from progressive disease. At a
median follow-up time of 11 months, 6 of 9 patients (66%) are
in continuous remission. We conclude that BEAM allogeneic
transplantation with early reduction in immunosuppression is
safe (no treatment related deaths) and effective in advanced HD
where autografts have failed. A graft versus lymphoma effect
after this conditioning appears to be a significant contributing
factor.
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OUTCOME OF ALLOGENEIC BONE MARROW TRANSPLANT IN RECIPI-
ENTS OF PRIOR HIGH-DOSE CHEMOTHERAPY: COMPARISON WITH
CASE-MATCHED CONTROLS
Daly, A.S.; Messner, H.A.; Hasegawa, W.S.; Kiss, T.L.; Lipton, J.H.
Princess Margaret Hospital, Toronto, ON, Canada
In order to determine the inﬂuence of prior transplants on the
outcome of alloBMT we examined 100-day non-relapse mortality,
1-year survival, median and overall survival of 45 consecutive
patients undergoing alloBMT following a prior auto or alloBMT.
Patients were eligible for a second BMT if they had good per-
formance status, adequate organ function and, in the case of
relapse or MDS/AML post-autoBMT, required retransplantation
> 1 year following the ﬁrst BMT and were in CR. Control patients
undergoing a ﬁrst alloBMT were matched for age, diagnosis and
donor type at second transplant. Patients with relapse or graft fail-
ure were matched for primary disease; patients with MDS/AML
post-autoBMT were matched to MDS/AML patients. Median age
of cases at second BMT was 44 (range 16-66) years vs. controls 42
(range 22-65) years. Diagnoses were (cases/controls) ALL (1/1),
AML/MDS(13/13), CML(18/18), MM(4/4), lymphoma(5/5) and
SAA (4/4). Donors were matched relatives(32/32), syngeneic(1/1),
mismatched relatives(5/5) or matched volunteers(6/6). In one case
a matched related BMT (case) was matched to a syngeneic BMT
(control). Indications for second BMT were graft failure (10),
MDS post autoBMT (5) and relapse (30). Median time between
transplants was 897 (range 33-5016) days. 100-day non-relapse
mortality (22% in cases and controls) was associated with a ﬁrst
BMT from a mismatched relative (p=0.037), first BMT for
AML/ALL (p=0.036) and retransplantation < 180 days after ﬁrst
BMT (p=0.037). Retransplantation from a mismatched relative
(p=0.053), for graft failure (p=0.084) or < 270 days after ﬁrst BMT
(p=0.087) approached signiﬁcance. Retransplantation < 360 days
after first BMT was associated with reduced 1-year survival
(p=0.037). Median survival of second BMT recipients was 270
days vs. 456 days for matched controls. Overall survival was 43%
and 48% respectively (p=0.60). Conclusion: With appropriate
patient selection the outcome of alloBMT in recipients of prior
transplants can approach that of a ﬁrst transplant.
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REDUCED TOXICITY CONDITIONING THERAPY WITH FLUDARABINE
AND IV BUSULFAN ± ATG FOR ALLOGENEIC TRANSPLANTATION IN
AML AND MDS; PRELIMINARY RESULTS
deLima, M.J.1; Shahjahan, M.2; Madden, T.L.3; Couriel, D.R.4;
Gajewski, J.L.5; Giralt, S.A.6; Donato, M.L.7; Russell, J.A.8; Cham-
plin, R.E.9; Andersson, B.S.10 1. UTMDACC, Houston, TX; 2. Tom
Baker Cancer Centre, Calgary, AB, Canada
Because of Fludarabine’s immunosuppressive and DNA damage
repair inhibiting activities, we combined it with IV Busulfan as
conditioning therapy prior to allogeneic transplantation for AML
and MDS. Fludarabine, 40 mg/m2 IV was given daily x 4, each
dose followed by Busulfan, 130 mg/m2 IV over 3 hr (days -6 till -
3). Nine patients who had an unrelated donor also received ATG
on days -3 to -1 with stem cells/marrow on day 0. Results: We
treated 3 MDS patient and 18 AML patients, 8 were refractory to
chemotherapy, 3 in untreated relapse, and 7 in CR. There were 10
males and 11 females with a median age of 44 years (21-57). All
patients engrafted (ANC 500) at a median time of 13 days (10-22),
the time to 20K platelets was 13 days (9-37), 2 individuals never
had <20K platelets. Sixteen patients were complete donor
chimeras by day 30 while 2 had 97 and 98% chimerism by PCR-
based microsatellite DNA polymorphisms, in 3 patients the results
are pending. Tolerance to the regimen was excellent without seri-
ous CNS toxicity or VOD. Transient hyperbilirubinemia (unre-
lated to GvHD) was seen in 2 patients. Mucositis grade 2 was
recorded in 9 and grade 3 in 2 patients. One subject developed
grade 3 hematuria, and one had transient pneumonitis. Treat-
ment-related mortality up to day 100 is Zero, but 3 patients died
of recurrent AML between days 30 and 100. Pharmacokinetic
analyses yielded the following mean (range) parameters for busul-
fan: plasma clearance 2.4 ml/min/kg (1.3-3.9), a daily AUC of
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5,516 µMol-min (3,990-8,271), and a half-life of 3.1 hours (1.6-
6.1), all of which are similar to parameters observed with a q 6-
hourly dosing regimen using 0.8 mg/kg/dose. We conclude: IV
Busulfan-Fludarabine is a well tolerated, low-risk conditioning
regimen for AML/MDS patients. Longer follow-up is needed to
assess progression-free survival.
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NONMYELOABLATIVE ALLOGENEIC TRANSPLANTATION AS A SAL-
VAGE THERAPY FOLLOWING A FAILED CONVENTIONAL HEMATOPOI-
ETIC STEM CELL TRANSPLANT (HSCT)
Feinstein, L.C.1,2; Sandmaier, B.M.1,2; Maloney, D.G.1,2;
Maris, M.B.1,2; Chauncey, T.R.1,3; Blume, K.4; Shizuru, J.A.4;
McSweeny, P.A.5; Forman, S.6; Agura, E.7 Pulsipher M.8
Niederweiser, D.9 Storb, R.1,2 1. Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2. University of Washington, Seattle, WA; 3. Seattle
VA Medical Center, Seattle, WA; 4. Stanford University, Stanford,
CA; 5. University of Colorado, Denver, CO; 6. City of Hope, Duarte,
CA; 7. Baylor University, Dallas, TX; 8. University of Utah, Salt Lake
City, UT; 9. University of Leipzig, Leipzig, Germany
Conventional allografting as salvage therapy following a failed
conventional HSCT is generally unsuccessful due to high nonre-
lapse mortality (NRM). We evaluated outcomes of 48 patients
(median age 44 [range 18-69] years) receiving a nonmyeloablative
regimen followed by HSCT from HLA matched related (n = 29)
or unrelated (n = 19) donors after autologous (n = 43), allogeneic
(n = 4), or syngeneic (n = 1) HSCT. Indications for nonmyeloabla-
tive HSCT included relapsed disease (n = 40), new secondary
malignancy (n = 6), both relapsed disease and new secondary
malignancy (n = 1), and autologous graft failure (n = 1). Diagnoses
included NHL (n = 15), HD (n = 12), MM (n = 8), advanced
MDS/secondary AML (n = 4), CML (n = 3), MF/MDS (n = 3),
acute leukemia (n = 2), and NHL/MDS (n = 1). The median time
from the most recent HSCT to nonmyeloablative allografting was
21.8 (range 1.8-126.3) months. Five patients had more than one
previous HSCT. Conditioning involved fludarabine, 30
mg/m2/day on days –4 to –2, and 2 Gy total body irradiation
(TBI) on day 0 (n = 41) or 2 Gy TBI on day 0 alone (n = 7). Post-
grafting immunosuppression was cyclosporine and mycophenolate
mofetil. One rejection occurred. With a median follow-up of 8.4
(range 0.6-31.5) months, 50% were alive; 29% were alive and dis-
ease free. Relapse mortality, day 100 NRM, and overall NRM
were 35%, 6% and 15%, respectively. Causes of NRM were graft
versus host disease (n = 3), infection (n = 4), and multiorgan failure
(n = 5); 6 of 7 patients had more than one cause of death. While
follow-up is short, this nonmyeloablative regimen appears to be
well-tolerated and capable of providing significant disease free
survival to a population of patients otherwise expected to have a
poor outcome.
55
RAPID ESTABLISHMENT OF DONOR CHIMERISM FOLLOWING NON-
MYELOABLATIVE STEM CELL TRANSPLANTATION
Filicko, J.; McGuire, L.; Brunner, J.; Ferber, A.; Grosso, D.; Mar-
tinez, J.; Wagner, J.L.; Flomenberg, N. Thomas Jefferson University,
Philadelphia, PA
Nonmyeloablative allogeneic stem cell transplantation (SCT) is
being used to provide graft-versus-tumor (GVT) effect. In animal
models, mixed chimeras have provided this GVT effect, but in
humans, mixed chimerism has been difficult to maintain with
patients either losing their grafts or converting to 100% donor
chimerism slowly following DLI. We have enrolled 23 patients
(median age-59, range 29-79) with HLA-identical or single anti-
gen mismatched donors in a phase II study of nonmyeloablative
SCT. Twenty-one patients evaluable for chimerism (11 sibling
donors, 10 MUD) had a diagnosis of hematologic malignancy
(AML-5, CML-2, CLL/SLL-3, NHL-8, MM-1, HD-1, ALL-1).
Eight (4-sibling, 4-MUD) had received prior autologous trans-
plants. All patients received fludarabine, ara-C and cyclophos-
phamide, followed by median cell dose of 8.16 X 10E8(range
3.49-24.5) TNC/kg and 5.99 X 10E6(range 0.76-14.93) CD34+
cells/kg. Three received marrow from unrelated donors, 18
received PBSC. All received cyclosporine and mycophenolate
mofetil. All evaluable patients demonstrated rapid engraftment
with median time to platelets >20,000/ul of 18(range 8-92) days
and median time to ANC>500/ul of 10(range 8-18) days. In the
matched sibling population, donor chimerism was >90% in 9/11
patients, in blood or marrow, by a median of 15 days(range 12-
126). 1 patient with CML never achieved >65% donor chimerism
and rejected by D+111, 1 with NHL never achieved >79% donor
chimerism but developed GVHD (skin, GI) and expired D+121.
Donor chimerism in MUD recipients was >90% in 8/10 patients,
by a median of 36 (range 17-70) days. One other had 84% donor
chimerism prior to expiring D+63 secondary to acute GVHD and
one succumbed to complications of GVHD and EBV-PTLD
D+51. All patients who had >80% donor cells by D+28 subse-
quently converted to 100% donor without DLI. The addition of
ara-C to fludarabine and cyclophosphamide may accelerate the
pace of conversion from host to donor lymphohematopoiesis.
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CHRONIC GRAFT–VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE
MARROW TRANSPLANTATION; AN ANALYSIS OF INCIDENCE AND
RISK FACTORS
Ghavamzadeh, A.; Alimoghaddam, K.; Bahar, B.; Foroughi, F.;
Jahani, M. Hematology-Oncology and BMT Research Center - Tehran
University of Medical Sciences, Tehran, Iran
Chronic graft-versus-host disease (cGVHD) is one of the most
serious potential complications of allogeneic bone marrow trans-
plantation. We analyzed the incidence of cGVHD and its associ-
ated risk factors in a group of 161 Iranian recipients of HLA-
identical sibling transplants surviving at least 90 days after
transplantation. In the majority of cases (n=73), cGVHD
occurred in the first year after transplant (median 273 days).
Actuarial probability of cGVHD at 1 year was 45.3+7% (CI
95%). In univariate analysis, the most important risk factor was
the type of transplant: Peripheral blood stem cell transplant
showed significant increase in cGVHD compared with bone
marrow transplant (RR=2.34 p<0.001). In addition, male recipi-
ents were at greater risk than female recipients (RR=2.08
p=0.004). Other risk factors were presence of prior acute GVHD
(RR=2.37 p=0.04) and previous acute GVHD grade (p=0.03);
The probabilities of cGVHD in patients with grade 0, 1, 2, 3, 4
acute GVHD were 24%, 44.7%, 42.6%, 56.8%, 64.3% respec-
tively. In multivariate analysis, the only independent predictive
factors for development of cGVHD were the type of transplant
(BBT>BM p<0.001) and male recipient (p=0.005). The probabil-
ity of survival was 88.8% and there was no significant difference
in the probability of survival between BPT vs BMT (93.8% vs
86.6% p=0.5).
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COMPARISON OF BMT AND PBSCT IN SHARIATI HOSPITAL IN
1995-1998
Ghavamzadeh, A.; Iravani, M.; Gharemani, M.; Bahar, B.;
Jahani, M.; Aghdami, N.; Mousavi, A. Hematology-Oncology and
BMT Research Center - Tehran University of Medical Sciences,
Tehran, Iran
We present the results of a historical cohort study comparing
autologous and allogeneic BMT, PBSCT, focusing on engraft-
ment, acute and chronic GVHD, plus overall survival, duration of
hospitalization and use of antibiotics. Patients and method: In this
study, 47 patients received BMT and 47 patients received PBSCT.
The disease, age, and sex of the two groups had already been iden-
tiﬁed. Conditioning was mainly Busulfan-Endoxan for allogeneic
transplantation and endoxan, VP16, and cytosar for autologous
transplantation. GVHD prophylaxis was, Cyclosporine,
methotrexate. PBSC was harvested after 3 days of G-CSF 10
µg/kg/d. Results: Median days for reaching PMN=500 9 in
PBSCT, and was 11 in BMT. (P value=0.17) Median days for
reaching platelet =20000 was 6 in PBSCT, and 8.5 in BMT. (P
value=0.22). Median days for hospitalization in autologous and
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allogeneic BMT was 32, and 50 days respectively. (P value=0.04)
Median days for hospitalization in autologous and allogeneic
PBSCT was 35, and 53 days respectively. (P value=0.02), Hospi-
talization was 44 days in PBSCT, BMT. (P Value=0.99) Duration
of antibiotics was 117 days in BMT and 72 days in PBSCT. (P
value=0.002). Acute GVHD was seen in 15% of BMT patients
and 22.6% of PBSCT patients (P Value=0.15). Chronic GVHD
was seen in 6.4% of BMT patients and 20.2% of PBSCT patients.
(P Value=0.003). Overall survival in the two groups showed no
significant difference. PBSCT reduces duration of antibiotics.
Acute GVHD showed no difference in the two groups. The inci-
dence of chronic GVHD was seen more in PBSCT than in BMT.
PBSCT reduces usage of antibiotics and quickens recovery time.
Conclusions: There is no significant difference between those
patients treated with BMT and allogeneic PBSCT, in grade III
and IV of AGVHD and extensive CGVHD.
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A PROSPECTIVE COMPARATIVE TRIAL OF HIGH DOSE THERAPY FOL-
LOWED BY ALLOGENEIC VERSUS AUTOLOGOUS STEM CELL TRANS-
PLANTATION IN 100 PATIENTS WITH HIGH RISK LYMPHOMA
Goldstein, S.C.; Perkins, J.; Janssen, W.E.; Field, T.; Smith, C.;
Loughran, T.; Sullivan, D.; Fields, K.K. H. Lee Mofﬁtt Cancer Center
and Research Institute, Tampa, FL
We update the results of 100 patients (pts) with lymphoma
enrolled in our single-center prospective trial of autologous
peripheral blood vs allogeneic bone marrow stem cell transplanta-
tion (SCT) following CBV as the High Dose Therapy (HDT) for
both arms. Although retrospective studies comparing relapse rates
after autologous vs allogeneic SCT have strongly suggested the
relevance of a ‘Graft vs Lymphoma’ effect after allo SCT, the
reduction in relapse rate has not yet translated into improved
overall survival (OS) or event-free survival (EFS) due to the higher
treatment-related mortality (TRM) associated with allo SCT. No
prospective trial comparing auto to allotransplantation while con-
trolling for the variables which may confound the interpretation
of retrospective series has been reported. In this study, adult
patients ≤55 yrs with NHL or HD who had either relapsed or
failed to achieve remission were eligible and offered allogeneic
SCT based on the availability of an HLA-identical sibling donor
in all patients who were deemed eligible for standard allotrans-
plantation. Probability of relapse and toxicity are the primary end-
points. 100 pts have undergone HDT/SCT: auto n=75; allo n=25.
When evaluated by stem cell source at 2 years, OS, EFS, Freedom
from Progression (FFP), and 100d TRM are 63±7%, 50±7%,
61±7%, and 7% respectively for auto; vs 53±12%, 40±11%,
71±11%, and 24% for allo. Though a trend toward higher FFP is
seen in the allo pts, a signiﬁcant difference in OS, EFS, and FFP,
has not yet been observed. There has been only one ‘late’ ( ≥6
months post-transplant) relapse among the 10 allo patients surviv-
ing beyond 6 months, with 4 patients beyond 3 years; whereas
relapse among auto pts continues late post-transplant, strongly
suggesting a beneﬁt from allotransplantation. Longer follow-up is
required to determine if this improvement in FFP will translate
into an OS advantage for standard allotransplantation.
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GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF)-PRIMING OF
ALLOGENEIC BONE MARROW DONORS INCREASES TOTAL CD4+ AND
CD4/CD8 RATIO IN GRAFT COMPARED TO RESTING BONE MARROW
Goldstein, S.C.; Smilee, R.; Burroughs, S.; Fields, K.K.; Smith, C.;
Janssen, W.E. H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL
Although the lymphocyte and CD34+ content of peripheral
blood stem cells mobilized with G-CSF has been extensively char-
acterized in the autologous and allogeneic transplant setting, little
is known regarding the cellular make-up of allogeneic bone mar-
row (BM) primed with G-CSF prior to harvesting from volun-
teers for use as progenitor cell rescue after myeloablative condi-
tioning. For laboratory correlates of progenitor, TNC, CD4+,
and CD8+ content, flow cytometric analysis was performed on
fresh BM samples from 40 volunteer sibling donors who had
received G-CSF 7.5ug/kg/D x 2D prior to harvest and compared
to fresh BM samples from 8 unprimed donors. To assess clinical
correlates of G-CSF priming (engraftment, GvHD, TRM), two
similarly treated sequential cohorts (primed n=22; unprimed
n=16) were analyzed. No difference in engraftment or GvHD
incidence was observed in these small cohorts. A trend toward
lower TRM (9% vs 25%) was observed for the primed group, but
was not statistically signiﬁcant. In summary, G-CSF priming prior
to BM harvesting increases the TNC and CD4+ content of the
graft, as well as CD4/CD8 ratio without a signiﬁcant increase in
CD34+ content. These data demonstrate a priming effect on rest-
ing BM resulting in the skewing of lymphoid subsets in the graft
toward the helper phenotype. The clinical/immunologic impact of
this effect on posttransplant immune reconstitution warrants fur-
ther study.
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EFFICACY OF STI571 IN PATIENTS WITH RELAPSED CML AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kim, D.1; Kim, Y.1; Kim, Y.1; Lee, Y.2; Oh, I.1; Kim, T.1; Han, T.3;
Min, C.1; Lee, S.1; Kim, C.1 1. Catholic Hemopoietic Stem Cell Trans-
plantation Center, The Catholic University of Korea, Seoul, South
Korea; 2. Soonchunhyang University, Bucheon, South Korea;
3. Sungkyunkwan University, Suwon, South Korea
Purpose : Primary options for managing relapsed CML after
transplant include interferon-α and adoptive immunotherapy
using DLI. We evaluated the efficacy of STI571, a specific
inhibitor of BCR-ABL tyrosine kinase, in patients who failed to
achieve remission after immunotherapies. Methods : Three
patients with relapsed CML, all of them had been previously
treated with DLI and/or interferon-α were included in use of
STI571. 400 or 600 mg/day of STI571 was given and hematologi-
cal, cytogenetic, and molecular response by fluorescence FISH
and real-time quantitative PCR (RQ-PCR) were analyzed. Results
: Complete cytogenetic responses were achieved in two patients
who also showed relapse in status of chronic phase and lymphoid
crisis. In those two patients, the reduction of BCR-ABL positive
cells by FISH was observed and the amount of BCR-ABL tran-
scripts by RQ-PCR was significantly decreased. Hematological
and non-hematological adverse effects were serious in one patient
who showed no response with STI571. Conclusion : We conclude
that STI571 may induce a signiﬁcant hematological, cytogenetic,
and molecular response in relapsed CML patients after transplant.
Even if the most of adverse effects are also tolerable, serious
cytopenia can be occured in some patients.
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THE ANALYSIS OF HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Kim, D.; Shin, H.; Park, C.; Park, Y.; Kim, Y.; Lee, S.; Min, C.;
Kim, H.; Min, W.; Kim, C. The Catholic University of Korea, Catholic
Hemopoietic Stem Cell Transplantation Center, Seoul, South Korea
Hemorrhagic cystitis (HC) is one of major causes of morbidity
during hematopoietic stem cell transplantation (HSCT), occur-
ring in 7-52% of transplant recipients. We analyzed the incidence,
risk factors, and complications of early- (≤ 4 weeks post-HSCT)
and late-onset (4 weeks - 100 days post-HSCT) HC in 378
patients undergoing HSCT between January 1998 and December
2000. HC occurred in 28 patients with an incidence of 7.4% and
24 of these 28 patients had severe HC, including urinary obstruc-
tion (2/24) and renal failure without dialysis (2/24). By univariate
analysis, disease of aplastic anemia and use of radiation were risk
factors for early-onset HC, whilst the use of busulfan was a risk
factor for late-onset HC. By multivariate analysis, use of busulfan
(RR=16.62; 95% CI=2.8-98.31) and aplastic anemia than other
diseases (RR=9.6; 95% CI=1.8-51.14) were unfavorable factor for
early-onset HC, as acute graft-versus-host disease ≥ II (RR=6;
95% CI=2.09-17.27) was for late-onset HC. Cyclophosphamide
was not a risk factor in this study, which might be due to the pro-
phylactic use of 2-mercaptoethane sulfonate (mesna), but high
dose cyclophosphamide (200mg/kg) had tendency to increase the
occurrence of HC in early post-transplant period (p=0.08). We
conclude that a higher dose of prophylactic mesna as well as vigor-
ous hydration/forced diuresis may be needed in patients with
aplastic anemia usually receiving high dose cyclophosphamide and
with those conditioned with busulfan.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT CHRONIC
MYELOMONOCYTIC LEUKAEMIA. A REPORT ON BEHALF OF THE
CHRONIC LEUKAEMIA WORKING PARTY OF THE EBMT
Kröger, N.1; Zabelina, T.1; Guardiola, P.2; Runde, V.3; Sierra, J.4;
van Biezen, A.6; Niederwieser, D.7; de Witte, T.5; Zander, A.1 1. Uni-
versity Hospital, Hamburg, Germany; 2. St LouisHospital, Paris,
France; 3. University Hospital, Essen, Germany; 4. Hospital St Creu i
Sant Pau, Barcelona, Spain; 5. University Hospital, Nijmegen, Nether-
lands; 6. University Hospital, Leiden, Netherlands; 7. University Hospi-
tal, Leipzig, Germany
Chronic myelomonocytic leukaemia (CMML) is a rare hemato-
logical neoplastic disease, characterised by increased monocytic
cells in the bone marrow and peripheral blood. We report the
results of 50 allogeneic transplantations performed in 43 Euro-
pean centers in 32 male and 25 female with CMML. The median
age at transplant was 44 years (r: 19-63), and the median time
from diagnosis to transplant was 9 months (r: 1-57). Donors were
HLA identical siblings in 38 cases, HLA matched unrelated in 6
cases, HLA mismatched related in 5 cases, and HLA matched
other related in one cases. Two graft failures were observed (4%).
Neutrophil engraftment (>500/mm3) and platelet engraftment
(>50000/mm3) was reached after a median of 17 days (r:11-50) and
29 days (r: 11-268), respectively. 26% experienced aGvHD grade
II-IV, while 18% developed severe aGvHD grade III/IV. 27
(47%) died of treatment related causes. After a median follow-up
of 29 months (r: 1-57) the 5 year estimated overall survival (OS) is
21% (95% CI: 12-30%) and the 5 year estimated disease-free sur-
vival (DFS) is 16% (95% CI: 11-21%). The following covariates
did not affect the outcome: recipient age, GvHD, donor gender,
cytogenetics and source of stem cells. Earlier transplantation in
the course of disease, male donor, use of no T-cell depletion of
the graft, and occurence of aGvHD were in favour for better DFS,
but the differences did not reach statistical significance. The 5
year estimated probability of relapse rate was 61 %. The lower
relapse probability of aGvHD grade(22% vs 66%; p=0.04), a trend
for higher relapse rate in patients with T-cell depleted grafts (73%
vs 52%) suggest that a "graft versus CMML effect“ might exist.
Allogeneic stem cell transplantation might cure a minority of
patients with CMML.
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PRETRANSPLANT ANTI-THYMOCYTE GLOBULIN (ATG) REDUCES
GVHD WITHOUT INCREASING RELAPSE IN GOOD RISK MYELOID
LEUKEMIA PATIENTS AFTER ALLOGENEIC TRANSPLANTATION FROM
MATCHED RELATED DONORS
Kröger, N.; Zabelina, T.; Krüger, W.; Renges, H.; Stute, N.;
Rischewski, J.; Sonnenberg, S.; Ayukatan, F.; Tögel, F.; Zander, A.
University Hospital, Hamburg, Germany
We investigated anti-thymocyte globulin (ATG) as part of
the conditioning regimen in HLA-related allogeneic stem cell
transplantation. 45 patients with good risk myeloid leukemia
(CML 1. chronic phase or AML 1. CR) were included and
compared with the results of 57 patients with the same diagno-
sis but conditioned without ATG. No graft failure was
observed in the ATG group, while one graft failure was seen in
the Non-ATG group. The median time to leukocyte engraft-
ment (>1 x 109/L) was 16 (range 12-33) in the ATG group and
17 days (range 11-29) in the Non-ATG group (n.s.). The
platelet engraftment (>20 x 109/L) was reached for the ATG
group after a median of 24 days (range 14-277) and for the
Non-ATG group after 19 days (range 11-34) (p=0.002). Acute
GvHD grade II-IV was observed in 47% of the Non-ATG and
in 20% of the ATG group (p=0.004). Severe grade III/IV
GvHD occured in 7% of the ATG and in 32% of the Non-
ATG group (p=0.002). Overall chronic GvHD was seen in
36% of the ATG and in 67% of the Non-ATG group
(p=0.005). Extensive cGvHD was more frequently observed in
patients conditioned without ATG (33% vs 17%, p=0.08). The
treatment related mortality did not differ in both groups. After
a median follow-up of 26 months (range 7-75) in the ATG and
of 65 months (range 1-126) in the Non-ATG group, the 5
years estimated overall survival is 66% (95% KI: 51-81%) for
the ATG group and 59% (95% KI: 46-72%) for the Non-
ATG group (n.s.). The 5 years estimated disease free survival is
64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%)
for the Non-ATG regimen (n.s.)The 5 years probability of
relapse was 5% in the ATG- and 15% in the Non-ATG group
(n.s.).
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BOTH CHARGES AND REIMBURSEMENT FOR REDUCED INTENSITY
PREPARATIVE REGIMENS (RIR)ARE COMPARABLE TO MYELOABLA-
TIVE REGIMENS (MR) IN MATCHED RELATED ALLOGENEIC STEM
CELL TRANSPLANT (ASCT)
LeMaistre, C.F.; Bachier, C.R.; Shaughnessy, P.J.; Wall, D.A.;
Cloud, R.S.; Cayce, K.; Alexander, L.; Gonzales, B. Texas Transplant
Institute, San Antonio, TX
RIR are associated with less early toxicity and may be less expen-
sive than MR. We studied 12 consecutive pts receiving RIR for
high risk malignancies, comparing them with 20 concurrent pts
receiving MR. RIR received Busulfan 3.2 mg/kg/day (d) x2, Flu-
darabine 30 mg/kg/d x4 and ATG 15mg/kg/d x3. MR received
Cytoxan 60mg/kg/d x2 with Busulfan 3.2 mg/kg/d x4 or TBI 12
Gy + VP-16 1500mg/m2. All pts received cryopreserved, mobi-
lized peripheral blood stem cells from matched siblings. GVH
prophylaxis was methotrexate and cyclosporine (RIR) or prograf
(MR). Inpatient (Ipt), outpatient (Opt) and transplant physician
(MD) charges to day 100 were analyzed. Median age (range) was
RIR: 56 (36-69) and MR: 41 (25-59) years, respectively (p= .008).
Median (range) CD34x106/kg was: RIR 5.3 (2.6-5.7) and MR 4.5
(2.8-8.9) respectively. Median time (range) to recovery of 500
ANC was RIR:14d (12-18) and MR:12d (9-17) while recovery of
20K platelets was 20d for both [ranges: RIR (0-94); MR (16-71)].
Median (range) of RBC transfusion [RIR 12 (0-44); MR 7 (2-22)
units] and platelets [RIR 8 (0-32); MR 5 (1-82) units] were not dif-
ferent. Median hospitalization to day 100 was 25d for both
(ranges: RIR 3-43; MR 2-44). Median (range) charges to 100d are
reported as percentages of median MR charges (table). Median
total charges for RIR were 14% more than MR, but both groups
displayed a wide range of charges. Collections for RIR for Ipt,
Opt, MD and total were 1.4, 1.1.,0.9 and 1.2, respectively, of MR.
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Programs performing RIR need to carefully assess resource uti-
lization for programmatic and contracting purposes. In a single
institution, reimbursement is comparable to that received for MR.
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MITOXANTRONE, ARAC, AND PENTOSTATIN: A NOVEL NON-MYE-
LOABLATIVE CONDITIONING REGIMEN (MAP REGIMEN) FOR HEMA-
TOLOGICAL MALIGNANCIES
Liu, D.; Seiter, K.; Kancherla, R.; Nelson, J.; Siddiqui, A.; Cereb, N.;
Yang, S.; Chiao, J.; Ahmed, T. New York Medical College and Zalmen
Arlin Cancer Institute, Valhalla, NY
We have developed a novel Non-myeloablative Stem Cell
Transplant (NST) conditioning regimen using Mitoxantrone,
AraC, and Pentostatin (MAP regimen) for patients with hemato-
logical malignancies. Allogeneic hematopoietic stem cells were
obtained from HLA-matched or one antigen-mismatched family
or unrelated donors. Donor leukocyte infusion (DLI) was given
following a dose-escalating schedule. 18 patients (12 M /6 F)
treated with this regimen are evaluable. Median age was 49 (26-
61). Among them were 7 NHL, 3 HD, 4 AML, 2 MDS-RAEBt, 1
CLL, 1 MM. 10/11 (except one with NHL) patients with NHL,
HD and MM had failed autologous progenitor cell transplanta-
tion. The 6 patients with AML/MDS/CLL were either in
advanced relapse or had poor prognostic factors. Median follow-
up time was 8 (4-17) months. Median time to ANC>500 was 12
days, and to Platelets>20 was 9 days. Median Donor chimerism
(MDC) at 1 month was 65% (20-100%, n=13) for related NST,
and 5% (0-20%, n=5) for unrelated NST. The MDC at >=3
months was 100% (<10%=3, 36%=1, 50%=1, 100%=6) for the
related NST. 4/5 patients with unrelated NST had primary graft
failure but all recovered with autograft. Overall, 1/18 pts had
GVHD on immunosuppression, 7/18 (42%) developed GVHD
later (Stage I-II=4, III-IV=3, the latter 3 developed after DLI).
Two patients died due to severe GVHD after DLI. Another ﬁve
patients died of disease progression. 3 of 7 pts (42%) with refrac-
tory NHL converted to and remained in CR at 12,15 and 15
months, respectively. To date, 6 out of 18 patients remained in
CR (37%). These data suggest that the MAP regimen was safe in
heavily pre-treated patients and can induce mixed donor
chimerism in a step-wise increasing fashion without early severe
GVHD. The 42% CR rate in these heavily pre-treated refractory
lymphoma patients was highly suggestive of grafte-vs-lymphoma
effect.
66
LOW INCIDENCE OF POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISORDER (PTLD) AFTER ALLO-BMT IN CHILDREN AND ADOLES-
CENTS WITH HEMATOLOGICAL MALIGNANCY: A REPORT FROM THE
CHILDREN’S CANCER GROUP (CCG)
Lones, M.1; Perkins, S.1; Sposto, R.1; Arceci, R.1; Gaynon, P.1;
Gross, T.1; Morris, E.2; Cairo, M.2 1. Children’s Cancer Group, Arca-
dia, CA; 2. Children’s Hospital of New York Presbyterian, Columbia
University, New York, NY
PTLD after Allo-BMT presents within one year as disseminated
disease frequently associated with a fatal outcome. PTLD is often
unrecognized until post-mortem examination. PTLD is more
common after T-cell depleted and mismatched Allo-BMT with
incidence as high as about 20% (Blood 86(10):217A, 1995). There
are few reports describing PTLD after Allo-BMT in the pediatric
age group. From 1986 to 2000, CCG employed Allo-BMT in
acute lymphoblastic leukemia (ALL) (1921, 1941, 1951, 1953) and
acute myeloid leukemia/myelodysplastic syndrome (AML/MDS)
protocols (2861, 2891, 2941, 2951, 2961). Records from patients
enrolled on Allo-BMT regimens were reviewed. HLA compatible
match was determined by serology for HLA A, B, and DR loci.
361 children and adolescents (age<21 years) underwent Allo-BMT
(90 ALL protocols, 271 AML/MDS protocols). BMT types: 325
matched related (match 6/6 or 5/6), 3 related (match 4/6 or 3/6),
33 unrelated (24 BMT, 9 cord blood). To date, there are no
recorded cases of PTLD (Follow-up ≥ 1 year in 97%). Within the
first year after Allo-BMT, 89 patients died and post-mortem
examination was performed in only 32 patients. In conclusion, the
incidence of PTLD appears very low or absent in pediatric Allo-
BMT for treatment of hematological malignancies on CCG stud-
ies. This may reﬂect the high proportion (90%) of matched relat-
ed donors for Allo-BMT, or under-recognition of PTLD since
many of the patients that died did not undergo post-mortem
examination. This low incidence of PTLD in this case group is
quite encouraging but requires further investigation to determine
the etiology of this observation.
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ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
WITH CD34 POSITIVE SELECTION FOLLOWED BY T-CELL ADD-BACK
IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
Magalhaes-Silverman, M.; Lee, C.K.; Hohl, R.; Schluter, A.;
Gingrich, R. University of Iowa, Iowa City, IA
Aim: To decrease the early morbidity and mortality from allo-
geneic hematopoietic stem cell transplantation while retaining the
graft-versus-tumor effect we initiated a pilot study of delayed T
cell add-back (TCAD) after CD34 selected peripheral blood stem
cell transplantation (PBSCT) in patients with advanced hemato-
logic malignancies. Study design: Twenty three pts were enrolled
in a trial of CD34 selected PBSCT followed by planned TCAD at
T+ 8-12 weeks and then 4-6 weeks later if no acute GVHD ≥II
was diagnosed. T cell dose ranged from 2.5x105 to 7.5x105/Kg
according to GVHD risk. Cyclosporin was used as GVHD pro-
phylaxis. G-CSF mobilized PBSCs from HLA identical siblings
were used for CD34 selection using the Isolex 300i system (n= 7)
or the Ceprate device (n=16). All pts were conditioned with TBI
containing regimen. Results: There were 12 males and 11 females
with a median age of 44 years ( range 25-59). Diagnosis included:
CML (3pts), AML (3pts), ALL (4pts), MM (4pts), CLL (1pt),
NHL (8 pts). The infused graft contained a median of
6.6x106CD34+ cells/Kg ( range 1.1-11.8)and a median of
4.7x105CD3+ cells/Kg using the Ceprate device and <1x105CD3+
cells/Kg with the Isolex 300i system. Seventeen pts survived 28
days. All but one engrafted . Only 2 pts received the planned
TCDA. Both developed acute GVHD ( grade II in one and IV in
the other). GVHD contribute to the death of them. Ten pts (
63%) developed acute GVHD prior to the planned TCAD infu-
sion. Seven of the 23 pts are alive at a median of 21 months after
transplant (6 in CR). Conclusion: In this study only 2 of 16 eligi-
ble pts received the planned TCAD. The major reason for not
receiving TCAD was acute GVHD. For this approach to be feasi-
ble further reduction of the T cell content of the graft is needed . 
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HIGH-RISK PATIENTS WITH A VARIETY OF HEMATOLOGICAL MALIG-
NANCIES SHOW TRANSIENT CR WITH FLUDARABINE-BASED CONDI-
TIONING PRIOR TO ALLOGRAFTING
Magalhaes-Silverman, M.1; Lee, C.K.2; Hohl, R.J.1; Schlueter, A.1;
Field, E.1; Gingrich, R.1 1. University of Iowa, Iowa City, IA; 2. Uni-
versity of Arkansas for Medical Sciences, Arkansas, AR
Patients of advanced age or with co-morbidities have traditional-
ly been ineligible for allografting. Fludarabine-based reduced-dose
conditioning is aimed at extending allogeneic transplantation into
these high-risk groups. Between April 1999 and June 2001, 14
high-risk patients (pts) (10 male, 4 female; median age 49 [range
25–67], 9 > 55 years; 5 had failed prior transplantation; 13 CMV
+ve) were treated for a variety of hematological malignancies (4
AML, 3 CML including 2 in AP, 1 secondary MDS, 1 HD, 1 amy-
loid, 2 NHL, 1 CMML, 1 MM). Allografting followed condition-
ing with fludarabine, 30mg/m2 x 3 and cyclophosphamide, 750
mg/m2 x 3. All pts received antiviral, anti-PCP and antibacterial
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prophylaxis. GVHD prophylaxis was mainly CSA + reduced-dose
methotrexate (11 pts). Autologous recovery occurred in 1 patient
(CML in AP), re-transplanted using the same donor. Blood and
BM donor engraftment were 87% (range 80–95%) and 90%
(range 80–95%), respectively, at day 30. CMV reactivation was
seen in 8 pts, with 4 viral enteritis cases (2 adenovirus, 1 HSV, 1
CMV) and 2 fungal infections. Six of 11 pts evaluable for GVHD,
had grade 3 or 4 GVHD, contributing to death in 3 pts. Extensive
chronic GVHD was observed in 3 pts. Six pts died before response
evaluation (day 60). Of the evaluable pts, 8 reached CR. However,
1 CML relapsed but re-achieved CR post-DLI and 1 died from
GVHD. The NHL and MM patients relapsed and did not respond
to DLI. To date, 4 pts continue in CR (one pt not yet evaluated for
relapse). Six pts are alive 20 months post-treatment. These data
indicate that while engraftment was successful, and many of these
high-risk patients achieved CRs, responses were mostly transient.
GVHD occurred despite prophylaxis. Opportunistic infections
were common, indicating a need for antimicrobial prophylaxis in
this high-risk patient population.
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SUBMYELOABLATIVE ALLOGENEIC BLOOD STEM CELL TRANSPLAN-
TATION WITH FLUDARABINE BASED REGIMENS IS HIGHLY ACTIVE
IN ADULTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES
Mangan, K.F.; Klumpp, T.R.; Sabol, P.J. Temple University, Philadel-
phia, PA
Patients with refractory multiple relapsed hematologic malig-
nancies usually cannot tolerate full myeloablative regimens with
allografting to exploit the graft-versus-tumor effect. To determine
the efficacy and toxicity of fludarabine (125 mg/m2) and
cyclophosphamide (120 mg/kg, FLU-CY) or melphalan (140
mg/m2, FLU-MEL) with mycophenolate (MMF) and tacrolimusj
(tacro), we transplanted 24 patients with refractory and/or high-
risk hematologic malignancies using G-CSF mobilized peripheral
blood stem cells from matched related (N=15) or matched unre-
lated (N=9) donors. Donor lymphocyte infusions (DLI) were
required in 25% of cases to induce full chimerism by Day 120.
Patients had a median age of 52 and 50% had failed prior auto-
graft and/or greater than two prior salvage regimens. Diagnosis
included 6 CML, 8 NHL (including 3 mantle cell, 2 large cell,
and 3 relapsed/transformed follicular NHL), 4 AML (including 2
secondary AML), 2 relapsed Hodgkin’s, 1 myeloma, 1 MDS, and
2 CLL/prolymphocytic leukemia. Three patients graft rejected
(12.5%) but all three achieved autologous recovery including one
patient following FLU-MEL. Chimerism studies documented a
more rapid switch to full chimerism (≥97% donor) with FLU-
MEL vs. FLU-CY. 60% of cases experienced Grade II-IV acute
GVHD or chronic GVHD. There have been 4/24 (16.6%) toxic
deaths, 3 due to GVHD. 2 patients with lymphoma relapsed and
died of disease after Day 100. Fourteen patients (58%) remain in
continuous complete remission greater than six months post-
transplant and four others are not yet avaluable. We conclude
that: (1) submyeloablative allogeneic blood stem cell transplanta-
tion with fludarabine based regimens in combination with
MMF/TACRO +/- DLI is an effective and safe regimen for
patients with refractory hematologic malignancies; (2) GVHD
deaths are less than expected in this heavily pretreated group; (3)
autologous recovery occurs after either FLU-CY or FLU-MEL
graft rejections, and (4) FLU-MEL allows a more rapid switch to
full donor chimerism than FLU-CY.
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AN ALTERNATE APPROACH TO ALTERNATE DONOR HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN HEAVILY PRETREATED PATIENTS
WITH HEMATOLOGIC MALIGNANCIES
Mookerjee, B.P.; Takebe, N.; Sarkodee-Adoo, C.; Fenton, R.;
Rapoport, A.; Kathy, R.; Phillips, G. University of Maryland
Greenebaum Cancer Center, Baltimore, MD
Conditioning regimen complications limit application of allogeneic
SCT in heavily pretreated patients. To derive anti-tumor effect of
donor T-cells in patients who lack a matched sibling donor we are
conducting a study to facilitate engraftment of donor hematopoietic
cells by immunosuppressing the host with a combination of
mycophenolate mofetil, tacrolimus, cyclophosphamide and daclizum-
ab followed by infusion of unmanipulated stem cells. If there is no
evidence of GVHD immunosuppression is withdrawn at day-60.
Sequential analysis of percentage donor hematopoiesis is carried out
and DLI is planned if there is less than 80% donor hematopoiesis
with no evidence of GVHD. Of the six patients enrolled, four had
secondary AML following autologous SCT, one with ALL and one
with AML (-7). All AML patients had active disease and the patient
with ALL had morphologic CR. Two with AML received stem cell
grafts from 4/6 HLA matched siblings, three (ALL-1 and AML-2)
received from matched unrelated donor and one (AML) from a one
antigen mismatched unrelated donor. All demonstrated quick
hematopoietic recovery and chimerism studies on day 30 after SCT
demonstrated at least 70% donor hematopoiesis in 5 of the patients
evaluated. No patient required DLI. Three patients had evidence of
skin GVHD that responded to steroids, one patient developed grade
4 gut GVHD and one patient developed chronic skin GVHD. Of
five patients with AML two are alive in CR one year and three
months post SCT, one had an initial response and subsequently died
of progressive disease, one died of fungal pneumonia >6 months post
SCT in CR and one of disseminated fungal disease with molecular
evidence of recurrence. The patient with ALL died in CR of CNS
toxoplasmosis. This approach is well tolerated and adequate to facili-
tate hematopoiesis from alternate donors as well as deliver the beneﬁ-
cial adoptive antileukemia immunotherapy.
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ALLOGENEIC NON-MYELOABLATIVE STEM CELL TRANSPLANTATION
FOR ADVANCED SYSTEMIC MASTOCYTOSIS: POSSIBLE INDUCTION OF
A GRAFT-VERSUS MASTOCYTOSIS EFFECT
Nakamura, R.1; Akin, C.2; Bahceci, E.3; Childs, R.1; Eniafe, R.1;
Greene, A.1; Young, N.S.1; Dunbar, C.E.1;  Leitman, S.F.4; Read,
E.J.4; Metcalfe, D.2; Barrett, J.1 1. National Heart, Lung, and Blood
Institute, Bethesda, MD; 2. National Institute of Allergy and Infectious
disease, Bethesda, MD; 3. Yale University, New Heaven, CT; 4.
Department of Transfusion Medicine, National Institute of Health,
Bethesda, MD.
Systemic mastocytosis is a disease originating from the
hematopoietic stem cell, characterized by excessive number of
mast cells in skin, bone marrow, and internal organs such as liver,
spleen, and lymph nodes. Patients with advanced mastocytosis
have a poorer prognosis, and there are no treatments known to
cure or improve the natural course of the disease. We thus evalu-
ated the possibility of controlling advanced systemic mastocytosis
by induction of a graft-versus-mastocytosis effect using non-mye-
loablative stem cell transplant (NMT). After informed
consent,two patients with advanced systemic mastocytosis received
a non-myeloablative conditioning regimen of cyclophosphamide
and ﬂudarabine, followed by a peripheral blood stem cell trans-
plant from an HLA-identical sibling. The first patient had
aleukemic variant of mast cell leukemia with soft tissue inﬁltration
and organomegaly. After the transplant, he developed three dis-
tinct episodes of acute GVHD ﬂare. Each episode was accompa-
nied by severe mast cell mediator release symptoms, suggesting
the possible interaction between the recipient mast cells and
donor allo-reactive T cells. The patient, however, never achieved
100% donor myeloid chimerism despite 100% donor T cells in
early post-transplant, and had progressive disease with worsening
pancytopenia. He died of invasive aspergillosis on day +170. The
second patient had systemic mastocytosis with associated
myelodysplastic syndrome requiring regular blood transfusions.
She achieved 100% donor T cell chimerism by day +30. She had
regression of the skin lesions around day +100, and by day +150,
she became transfusion-independent and achieved 100% donor
myeloid chimerism. Her bone marrow biopsy revealed morpho-
logically normal hematopoiesis with small residual mast cell
aggregates. Her serum tryptase level decreased from 150 to 88.
Her response occurred at the time of cyclosporine withdrawal and
onset of skin GVHD, highly suggestive of a graft-versus-mastocy-
tosis effect. Together, these two cases demonstrate that the graft-
versus-mastocytosis effect can be induced in NMT, and potential-
ly leads to disease regression.
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OUTCOME OF 48 PATIENTS UNDERGOING ALLOGENEIC BONE MAR-
ROW TRANSPLANT WITH A REDUCED INTENSITY PREPARATIVE
REGIMEN OF PHOTOPHERESIS, CONTINUOUS INFUSION PENTO-
STATIN AND REDUCED DOSE TBI
Roberts, T.F.; Klein, A.; Sprague, K.; Grodman, H.; Chan, G.;
Relias, V.; Mahajan, A.; Schenkein, D.; Foss, F.; Miller, K.B. New
England Medical Center, Boston, MA
Between 1/2000 and 11/2001, 48 patients underwent allogeneic
BMT with a novel reduced intensity regimen consisting of extra-
corporeal photopheresis, CI pentostatin, and reduced dose TBI.
Patient characteristics include: median age 46 years (range 18-70);
M:F=26:22; 14 patients had previous transplants (13 auto, 1 allo);
diseases included AML/MDS (n=20), lymphoma (n=13), CML
(n=7), renal cell carcinoma (RCC) (n=3), myeloﬁbrosis (n=2), MM
(n=2) and PNH (n=1). Thirty-seven patients received related bone
marrow (32 6/6, 5 5/6), 2 patients 6/6 HLA matched related
donor PBSC, and 9 patients received 6/6 MUD-BMT. Twenty-
three patients had sex-mismatched donors. Recipient/donor CMV
status was 13 +/+. At a median time of 235 days post transplant
(range 2-672), 36 patients (75%) are alive. The median time until
ANC >500/uL was 17 days (range 9-39), and median time to
platelet engraftment was 21 days (range 11-185). For all patients,
1-year actuarial OS is 68% (95% CI 51, 85) and 1-year actuarial
EFS 65% (95% CI 48, 82). One-year actuarial PFS is 89% (95%
CI 79, 99). The 100-day OS is 86% (95% CI 75, 97). Patients
who had less than 3 previous chemotherapy regimens and no prior
transplant had a statistically signiﬁcant improved 1-yr OS (81% vs
53%, p=0.01) Disease specific 1-year OS rates are: AML/MDS
61% (95% CI 37, 85), CML 100%, and lymphoma 64% (95% CI
30, 98). Two patients with RCC are alive at 79 and 177 days post
transplant. Two patients with myeloﬁbrosis are alive at 198 and
282 days post transplant, one in CR with complete reversal of
marrow fibrosis, and 1 in PR. Cause of death in 12 patients
include progressive disease (4), multi-system organ failure (6), car-
diac arrest (1), and HUS/intracerebral bleed (1). In 42 patients
assessable for acute GVHD, 7% had >= grade 2 aGVHD. Forty-
eight percent had no aGVHD.
73
HLA-B MATCHING OF UNRELATED PEDIATRIC UMBILICAL CORD-
BLOOD (UCB) TRANSPLANTS CORRELATES WITH RELAPSE FREE
SURVIVAL (RFS). EXPERIENCE FROM ONE CENTER
Rodriguez-Marino, S.1; Stephan, B.1; Coquillard, G.1; Haut, P.R.1;
Liu, D.2; Rademaker, A.2; Kletzel, M.1 1. Childrens Memorial Hospi-
tal, Chicago, IL; 2. Department of Preventive Medicine, Northwestern
University, Chicago, IL
UCB transplants from unrelated donors have been used as an
effective treatment for children with malignant and non-malig-
nant disorders. We analyzed hematopoietic reconstitution, inci-
dence and severity of graft versus host disease (GVHD) and its
relationship to HLA matching to evaluate their outcome. From 7-
6-1995 to 12-27-2000, 46 children underwent unrelated UCB
transplants at Children’s Memorial Hospital. Recipients had non-
malignant disease (N=9) and malignant disease (N=37); females
(N=21), males (N=25); mean age at diagnosis 4.48 years; mean age
at transplant 6.5 years; mean mononuclear cells infused 0.52 x 108
/kg. HLA typing was performed using DNA methods (DRB1) and
serological methods (HLA-A and B). Statistically signiﬁcant vari-
ables on overall survival from time of diagnosis (TD) and time of
transplant (TT) were: outcome of acute GVHD (resolved
N=22)(P=0.006, P=0.003) and engraftment (N=32) (P=<0.0001,
P=<0.0001). From TD, absence of relapse (N=39)(P=0.0003).
From TT, presence of acute GVHD (N=28) (P=0.02) and absence
of graft failure (N=39) (P=0.0003). Patients with acute GVHD
had higher probability of 6 months survival (6MS) than patients
without GVHD (82% vs. 39%). Patients with RFS from TT with
1 HLA-B match (N=27) had 96% 6MS, 2 HLA-B matches (N=14)
93%, and 0 HLA-B matches (N=5) 60% (P= <0.0001). Although it
is known that unrelated cord-blood transplant recipients tolerate a
higher degree of HLA mismatching, the effect of HLA matching
in unrelated cord-blood transplants has not been clearly demon-
strated. In this study we demonstrate that HLA-B serological
matching is a significant factor in determining the outcome of
unrelated cord blood transplant recipients.
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TRANSPLANTATION OF ALLO- PBPC AFTER NON-MYELOSUPPRES-
SIVE CONDITIONING- A PHASE I/II TRIAL OF SINGLE-AGENT PENTO-
STATIN AS AN INNOVATIVE PREPARATIVE REGIMEN FOR ALLO-
TRANSPLANTATION FOR KIDNEY CANCER
Schiller, G.J.; Emmanouilides, C.; Spaargaren, C.; Territo, M.;
Gitlitz, B.; Figlin, R. UCLA, Los Angeles, CA
Allogeneic peripheral blood progenitor cell transplantation for
advanced renal cell carcinoma produces regression of metastatic dis-
ease presumably through a mechanism of adoptive immunotherapy.
The purpose of conditioning is to induce sufﬁcient immunosuppres-
sion in the recipient to permit engraftment of immunoreactive donor
cells. In order to simplify the immunosuppressive regimen used for
conditioning in this setting, we initiated a Phase I/II dose-escalation
trial of a novel agent, Deoxycoformycin, as the only drug in a prepar-
ative regimen prior to allogeneic transplantation for metastatic kid-
ney cancer. Pts were eligible for allo tx from an histocompatible sib-
ling donor if they had pathologically confirmed advanced renal
cancer unresponsive to immune therapy. 4 Patients were enrolled at
dose levels of Deoxycoformycin 1.75, & 2.5 mg/m2 by IV bolus for 3
doses on days -7, -5, and -3. A target of > 4 x 106 G-CSF-mobilized
allo CD34-positive cells were infused on day 0. Post-Tx immunopro-
phylaxis consisted of CSA (2 mg/kg orally every 12 h) in all pts and
prednisone (1mg/kg/day) in 3 pts. Pts were followed by immunophe-
notype of lymphocyte subsets, and for engraftment by either FISH
or RFLP weekly for four weeks and thereafter as clinically indicated.
Pts were eligible for infusion of unstimulated donor leukocytes 1
month after tx for incomplete chimerism. Preparative conditioning
was well tolerated with no tx-related myelosuppression, however
CD4-cytopenia occurred. At the lowest dose, full engraftment could
be demonstrated after unstimulated DLI, although the pace of donor
chimerism, time to development of GVHD, and time to tumor stabi-
lization/response were delayed; e.g., in pt.1, these events occurred at
d + 74, + 71, and + 126, respectively. If conﬁrmed in a sufﬁciently
large cohort of pts, single-agent Deoxycoformycin may prove an
acceptable preparative agent for nonmyeloalbative allogeneic trans-
plant allowing for adoptive immunotherapy of solid tumors without
myelosuppression or signiﬁcant regimen-related toxicity.
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ANALYSIS OF T-CELL KILL DURING THE BUSULFAN (BU) CYCLOPHOS-
PHAMIDE (CY) ETOPOSIDE (VP16) PREPARATIVE REGIMEN
Schwartz, J.E.; Griffin, D.L.; Yeager, A.M.; Kiss, J.E.;
Donnenberg, A.D. University of Pittsburgh, Pittsburgh, PA
INTRODUCTION: In allogeneic hematopoietic stem cell
transplantation (HSCT) the immunosuppressive component of
the preparative regimen facilitates engraftment of donor T cells
capable of mediating graft vs. tumor effects. Immunosuppression
is also critical for the treatment of severe autoimmune diseases
with autologous HSCT. In order to gauge the relative immuno-
suppressive efﬁcacy of preparative regimens, we developed a sin-
gle-platform ﬂow cytometry based assay capable of quantifying T
cells down to 0.1 cells per microliter. METHODS: In a bead-cali-
brated lyse/no-wash assay CD45+/CD3+/7AAD- are identiﬁed as
viable T cells. Depending on the WBC, 3 to 9 replicate tubes con-
taining up to 200 microliters of whole blood are exhaustively
acquired. T-cell counts are determined daily from the day preced-
ing initiation of the preparative regimen through day 7 post trans-
plant. RESULTS: T-cell counts decreased as a function of time
after initiation of the preparative regimen. Even at the lower limit
of detection, coefﬁcients of variation did not exceed 15%. After an
initial shoulder, the decrement in T-cell count was log-linear until
the onset of T-cell engraftment at approximately day 5. T-cell kill
was expressed in terms of “half-life”, calculated as –1/b, where b is
the slope of the regression of the linear portion of log2(T-cell
count) vs. time in days. In a series of 6 patients receiving Bu(4
mg/kg)-Cy(120 mg/kg)-VP16(30 mg/kg), the mean T-cell half-
83B B & M T
Poster Presentations - Session I
life was 2.5 days (95% CI= 2.1 to 3 days). WBC kill followed a
steeper trajectory: mean WBC half-life was 1.4 days (95% CI= 1.1
to 1.8). CONCLUSION: We have deﬁned the trajectory of T-
cell kill for a known immunoablative regimen. This may be used
as a standard of comparison for reduced intensity regimens. It is
possible that T cells detected at low levels in the present assay may
not be fully functional. We are now investigating mitochondrial
activity as a predictor of function.
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PHARMACOKINETICS (PK) OF ONCE DAILY DOSING OF INTRA-
VENOUS BUSULFAN (IVBU) IN A REDUCED INTENSITY PREPARATIVE
REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT)
Shaughnessy, P.J.1; Tran, H.3; Andersson, B.S.3; Nguyen, J.3;
Splichal, J.2; Alexander, W.2; Ornstein, D.2; Ririe, D.2; Bachier, C.1;
LeMaistre, C.1 1. Texas Transplant Institute, San Antonio, TX;
2. Wilford Hall Medical Center, San Antonio, TX; 3. University of
Texas MD Anderson Cancer Center, Houston, TX
IVBU has widely replaced oral BU as a preparative drug for ASCT
because of more consistent bioavailability. Initial PK data of IVBU
was based on 4 times daily dosing to replicate the known oral sched-
ule. We report our experience with a prospective phase I/II trial
using IVBU (Busulfex, Orphan Medical, Minetonka, MN.) once
daily as part of a reduced intensity conditioning regimen for ASCT.
Twelve patients (pts) have been treated on protocol, 11 male, with a
median age of 48. The preparative regimen consisted of IVBU
3.2mg/kg/dose given once daily on D-9 and D-8, fludarabine
30mg/m2/dose once daily D-6 to D-2, and in the ﬁrst 9 pts equine
ATG 15mg/kg/dose once daily D-4 to D-1. Five pts had greater
than grade II mucositis, nausea, vomiting, diarrhea, or bilirubin ele-
vation. One pt had moderate hepatic veno occlusive disease of the
liver and renal insufﬁciency that resolved spontaneously. All evalu-
able pts engrafted, and 5 pts developed acute GVHD. The mean
dose of IVBU administered was 2.99 +/- .24mg/kg/dose. Drug
clearance and AUC were determined by ﬁtting a 1-compartment
model to the concentration-time points obtained with the 1st and
2nd dose using weight-least squared estimation. Preliminary PK
data are available in 6 pts. and shown below. There were no signiﬁ-
cant differences in the PK parameters for the group between the 1st
and 2nd dose. The drug was rapidly cleared and no increase in the
AUC was seen with the 2nd dose. Once daily dosing of IVBU has an
increased AUC that is proportional to the increased dose when
compared to the known AUC of the same dose divided 4 times daily.
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INTRAVENOUS BUSULFAN REDUCES TREATMENT-RELATED TOXICITY
AFTER ALLOGENEIC TRANSPLANTATION FROM MATCHED UNRELAT-
ED AND MISMATCHED RELATED DONORS
Shimoni, A.; Bielorai, B.; Hardan, I.; Avigdor, A.; Toren, A.;
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Hematopoietic transplantation from unrelated and mismatched-
related donors is associated with high incidence of treatment-
related complications. Intravenous busulfan (IV bu) was recently
introduced into clinical practice. This formulation circumscribes
the erratic absorption of oral bu and reduces the risks of over and
under-dosing when using ﬁxed oral dosing. IVbu may also reduce
hepatic toxicity by the elimination of ﬁrst-pass effect through the
liver. In this study we investigated if IVbu can reduce toxicity
associated with high-risk transplants. The study included 12
patients at median age 24 (2-48). Eight had AML, 3 ALL, 1 CML.
All had advanced leukemia or first CR with high-risk features.
Ten patients were given IVbu (0.8 mg/kg x 16 doses) combined
with cyclophosphamide (120 mg/kg). Two patients with extensive
prior therapy were given 12 doses of bu combined with ﬂudara-
bine and ATG. Nine patients were given allografts from unrelated
donors and three from 1-antigen mismatched related donors. All
patients engrafted at median of 13 days post-transplant. One
patient had severe TTP. None of the others sustained >grade II
organ toxicity. Grade I-II mucusitis was observed in most patients.
Transient elevation of bilirubin was common but none developed
VOD. Four developed transient grade-II hemorrhagic cystitis.
Acute GVHD occurred in 6 patients (50%) and was severe in 3.
Chronic GVHD occurred in 6 of 9 evaluable patients (67%) and
was extensive in 3. With median follow-up of 8 months (2-15). 10
patients are alive and disease-free and two have died of relapse.
None died of treatment-related complications. The projected 1-
year DFS is 77% (95%CI 63-91%). In conclusion IVbu contain-
ing regimens allow consistent engraftment of allografts from
unrelated and partially matched related donors with reduced toxi-
city and improved short-term outcome. Longer follow-up of a
larger group of patients is required to assess the impact on relapse
incidence and long-term outcome.
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DEVELOPMENT OF NON-MYELOABLATIVE TRANSPLANTS: A DISEASE
SPECIFIC PROGRAM
Van Hoef, M. Transplant Creations, L.C., Falls Church, VA
Literature review and retrospective analysis of transplant reg-
istry data are honorable efforts to obtain insight in outcome
parameters and an elegant way to identify prognostic factors.
Multicenter prospective clinical studies are required to develop
non-myeloablative transplants into strategies that can become
recognized therapies. Transplant Creations supports improve-
ment of clinical research in transplantation in the best interest
of patient care, economics and investigators. Breast cancer, for
which transplantation is currently most contradictory, was
selected to develop a treatment strategy using transplant
modalities that can improve outcome. The program follows
scientific and ethical principles and has been designed based on
evidence such that the overall strategy has a strong foundation
and logistics can be developed out according to study findings
and timely evaluation of such during the study course. The
program has been written as development plan to evaluate non-
myeloablative transplants for breast cancer. The first study of
the plan for patients presenting with early advanced breast can-
cer has been submitted as grant application to funding agencies
with the goal to generate funding for establishment of the
study as a collaborative project among qualifying study centers,
and to offer the opportunity to set-up a system that offers
equal opportunity for those who commit and contribute to
study participation. Establishment of the program in several
countries, offers opportunities per country while the program
becomes an international study that can result in development
of a therapy option that becomes recognized and established.
Fully aware of the work burden involved in this type of trans-
plant strategy development, the author, dedicated and motivat-
ed to support collaboration between investigators, an important
requirement for successful development, believes that it is fea-
sible to establish such project and has started the initiative out
of pocket. Further details will be presented orally during the
meeting.
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LONG-TERM FOLLOW-UP OF MYELOID LEUKEMIA PATIENTS IN TWO
CLINICAL TRIALS OF MATCHED RELATED DONOR TRANSPLANTA-
TION USING A BUSULFAN BASED PREPARATIVE REGIMEN, CD-34
SELECTED PBPC AND PRE-TRANSPLANT ATG
Vaughan, W.P.1; Katz, R.O.1; Garcia, A.1; Pena, O.B.1;
Salzman, D.E.1; Tilden, A.B.1; Carabasi, M.H.2 1. UAB, Birming-
ham, AL; 2. USC, Los Angeles, CA
From 7/96 through 7/99 we treated 22 patients age 28 to 57
(median - 43)with AML in 1st (N=6) or 2nd (N=2) remission or
CML (11 in CPh1 and 3 more advanced disease) using a BuCy(2)
preparative regimen plus equine ATG (15mg/Kg d -4 through -1).
Donors were given G-CSF for 4d prior to PBPC collection.
CD34+ cell concentration used the CellPro (N=8) or Baxter
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(N=14) device. A range of 3.6 to 27.5 (median 5.7) X 106 CD34+
cells and 2.2 to 23.4 (median 7.4 X 105 CD3+ cells were trans-
planted. GVHD prophylaxis consisted of cyclosporin A and low
dose methotrexate (10 mg/M 2 on day 1 followed by 5 mg/M2 on
days 3, 6, 13 and weekly to day 100). An AGC of 500/µL was
achieved by all patients by day 19 (median 14 days). There was no
significant acute pulmonary toxicity. The median peak bilirubin
was 1.8 (highest 8.8), and the median peak creatinine was 1.6
(highest 2.5). There were no regimen related deaths. GVHD
beyond grade 2 occurred in only 1 patient. Only 1/8 AML patient
has relapsed (day 435). This patient died following a second trans-
plant. The remaining 7 have PFS from 997 to 1197 days. Two of
11 patients with 1st chronic phase CML died of fungal infection
on days 81 and 109, but the remaining 9 are alive from 1010 to
1873 days. Five of these have relapsed but have disease control
after DLI or Gleevec. Two of the 3 more advanced CML patients
are alive with recurrent disease and one has died. While the recur-
rence rate for CML is of concern, 7/8 patients with AML and
11/14 patients with CML alive and well with a minimum follow
up of 27 months is encouraging with this very well tolerated
approach to allogeneic BMT.
GVH/GVL
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LOBULAR HEPATITIS AS A PRESENTATION OF LIVER GVHD AFTER DLI
Akpek, G.; Lee, L.A.; Hallick, J.P.; Boitnott, J.K.; Jacobsohn, D.;
Anders, V.; Arai, S.; Vogelsang, G.B. The Johns Hopkins University
School of Medicine, Baltimore, MD
GVHD of the liver is characterized by bile duct injury and lympho-
cytic inﬁltration. In this case series, we report an acute hepatitis-like
presentation of liver GVHD after donor lymphocyte infusion (DLI).
Between 4/1998 and 9/2001, a total of 22 patients with a median age
of 43 developed liver GVHD after receiving DLI with (n=7) or with-
out (n=15) prior chemotherapy. Ten patients received CD3+ cells at
a dose of ≤5x10(7) and 12 had ≥1x10(8) cells/mm3. Median interval
from the DLI to the observation of liver function (LFT) abnormali-
ties was 35 days (range 11 to 406). Liver GVHD with (n=18) or with-
out (n=4) skin and/or gut involvement was diagnosed within 4 days
(range 0 to 25) following the onset of LFT abnormalities. The medi-
an ALP, SGOT, SGPT and total bilirubin levels at GVHD were 305
(106 to 1967 ), 191 (22 to 1256), 250 (54 to 1540), and 1.3 (0.4 to 7),
respectively. After ruling out viral infection and drug toxicity, 14
(64%) patients were diagnosed as having a component of hepatitis-
like liver GVHD based on transaminase elevations. Nine (64%) and
6 (43%) of the 14 patients had SGOT or SGPT levels ≥300U/L and
≥500U/L, respectively. Histopathologic features conﬁrmed the diag-
nosis of lobular hepatitis in 5 (33%) of the 15 cases who underwent a
liver biopsy. There was no signiﬁcant association between hepatitis-
like presentation and clinical variables including the CD3+ cell dose.
GVHD progressed in 14 (64%) patients despite treatment. Of note,
15 (68%) patients developed lichenoid chronic GVHD in a median
of 27 days (0 to 324) after the occurrence of acute GVHD post-DLI.
Five (33%) had chronic GVHD at initial presentation. This unaccus-
tomed presentation of liver GVHD raises the possibility of a differ-
ent pathogenesis in the development of GVHD after DLI. A follow-
up study is underway to substantiate this hypothesis.
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EXTRACORPOREAL PHOTOPHERESIS PLUS UVADEX® IN CHRONIC
GRAFT-VERSUS-HOST DISEASE (C-GVHD). PRELIMINARY REPORT
Bouzas, L.S.1; Silva, M.M.2; Mota, I.F.1; Brito, S.M.1;
Diamond, H.R.1; Vasconcelos, Z.1; Romano, S.1; Guadagnino, M.M.1;
Filgueira, A.L.2; Tabak, D.G.1 1. INCA, Rio de Janeiro, Brazil;
2. Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
We report results of the Brazilian protocol using Extracorporeal
Photopheresis (ECP) for chronic GVHD. Efficacy of ECP was
evaluated in patients with severe cGVHD after allogeneic BMT.
Method: 6 patients were treated with ECP plus UVADEX for
extensive cGVHD from Nov/00 to Oct/01. The protocol consist-
ed of 2 consecutive daily ECPs every week for the ﬁrst 5 weeks,
followed by clinical and lab evaluation and maintenance with 2
ECPs every other week for 16 weeks. Results: 2 patient are in
complete response 5 months and 1 week after stopping ECP; 4 pts
are in Partial remission (PR) after 23, 20 and 20 ECPs respective-
ly; one pt with Multiple Mieloma was excluded after 12 ECPs in
PR with a secondary malignancy after his second BMT. One
patient in PR had to interrupt treatment due to Herpes Zoster
infection and peripheral venous access difﬁculties. No severe side
effects were detected, the peripheral venous access was well toler-
ated and immunossupression could be reduced or withdrawn in all
6 cases with more than 10 ECPs. One patient with complete
response had signiﬁcant improvement of contractures and is out of
immunessupressive treatment. Liver function tests improved in all
6 patients. Conclusion: ECP is effective in treating skin, oral
mucosa and liver severe chronic GVHD. We considered staff
training, patient selection, early indication and long term follow
up essential for successfully development of this program.
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A PILOT STUDY OF TACROLIMUS (FK-506) AND MYCOPHENOLATE
MOFETIL (MMF) FOR GVHD PROPHYLAXIS IN ALLOGENEIC RELATED
AND UNRELATED SCT (ALLO SCT)
Cairo, M.S.; Harrison, L.; Bessmertny, O.; Ellis, H.; Wolownik, K.;
Wischhover, C.; Del Toro, G.; Bradley, M.B.; Yamashiro, D.;
Garvin, J. Children’s Hospital of New York Presbyterian, Columbia
University, New York, NY
FK506/MMF is effective salvage therapy for steroid-resistant
chronic (C) GVHD (Mookerjee et al, BMT 1999; 24:517-20), but has
not been evaluated for acute (A) or C GVHD prophylaxis. We treat-
ed 14 patients (pts) (age 2-22 years, median 13.5 years, 9 male) under-
going allo SCT for hematologic malignancies (11) and nonmalignant
diseases (3) with a regimen of FK506 0.03 mg/kg/day by CIVI start-
ing day -1 and MMF 15 mg/kg PO/IV BID starting day +1. Median
duration of MMF and FK506 was 48 (28-127) and 58 (15-166) days,
respectively. HLA typing was serologic for A and B and high resolu-
tion for DRB1. Stem cells were UCBT (3 5/6 class I mismatch, and 6
4/6 match [M] [3 class I, 1 class II, and 2 class I/II double mismatch]),
related (R) PBSC (3 6/6 M), and R BM (2 6/6 M). FK506/MMF was
well tolerated, 1 grade 3 neurotoxicity (disorientation). Among 11
evaluable pts (median follow-up 2.6 months, range 0.6-11 months),
median to ANC >500/mm3 x 2 days was 14 days (11-17) and 24 days
(3-79) following R PBSC/BM and UCBT, respectively. Three evalu-
able patients (28%) developed AGVHD: reversible grade II (skin),
grade II (intestinal), and 1 grade IV. The incidence of severe (grade
III/IV) AGVHD was only 9%, and no patient developed CGVHD.
There were 6 documented opportunistic infections and 5 deaths (pul-
monary hemorrhage, AIHA, Pseudomonas, adenovirus, and PD).
These preliminary results suggest FK506/MMF is safe and non-
myelosuppressive and may be an effective MTX and steroid-sparing
GVHD prophylaxis regimen following R and UCB allo SCT. Fur-
ther studies comparing this regimen to MTX and/or steroid contain-
ing regimens are required to compare efﬁcacy and/or complications.
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CD8 PEPTIDE INHIBITOR AFFECTS CD8+ T CELL-DEPENDENT
RESPONSES IN A MURINE MODEL OF GRAFT VERSUS HOST DISEASE
Choksi, S.; Cheney, K.; Korngold, R. Thomas Jefferson University,
Philadelphia, PA
Cytotoxic T lymphocytes (CTL) play a signiﬁcant role in cell-
mediated immune responses and are directly involved in the
killing of virus-infected cells, tumor cells, and allogeneic graft cells
resulting in transplant rejection. CD8+ T cells can mediate lethal
GVHD directed to either MHC class I mismatches or minor his-
tocompatibility antigen differences. Using theoretical analysis, we
searched for surface regions as potential functional epitopes to
serve as the basis for a panel of synthetic cyclized peptides from
the C’’D and DE loops of hCD8α molecule. Previously, these
peptides were tested for their inhibitory effects in human CML
assays. The DE loop peptide, 1109, was found to be most effective
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with 92% inhibition of speciﬁc lysis of target cells. Here, we test-
ed 1109 in the B10.BR->CBA/J strain combination model of
GVHD. We demonstrated a signiﬁcant prolongation of survival
in the experimental recipient group treated with a single dose of
1109. The untreated mice exhibited 100% fatality by day 36 post-
transplant with a MST of 33 days. Transplanted mice given 1109
(0.5 mg, day 0) had signiﬁcantly increased survival (40%) with a
MST of 47 days. To examine the effect of 1109 on CD8+ T cell
responses, B10.BR mice were injected with irradiated CBA/J
splenocytes (15x106; footpad) and treated with either PBS or 1109.
CD8+ T cells from the draining lymph nodes were isolated and
standard mixed lymphocyte reactions were used to measure prolif-
erative responses of these cells against either CBA/J, third-party
C57BL/6 or syngeneic B10.BR splenocytes. Both CD8+ T cells
treated with 1109 or PBS had similar proliferative responses
against third-party C57BL/6, but the response against the CBA/J
was signiﬁcantly diminished suggesting that the 1109 speciﬁcally
inhibited the allogeneic response without affecting the third-party
response. Thus, 1109 may prove to be a therapeutic with potential
application in the clinical transplantation settings.
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GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER NON-MYELOABLATIVE
(NMA) VS MYELOABLATIVE (MA) CONDITIONING IN FULLY
MATCHED SIBLING DONOR TRANSPLANTS: AN UPDATE
Couriel, D.R.; Giralt, S.; Khouri, I.; Andersson, B.; Cohen, A.;
De Lima, M.; Saliba, R.; Champlin, R. UT MD Anderson Cancer
Center, Houston, TX
Objective: To evaluate the differences in incidence, clinical features
and impact of GVHD after NMA vs MA transplants. Design: Retro-
spective, descriptive study. Material/Methods: Eighty patients receiv-
ing NMA allogeneic hematopoietic stem cell transplants (HSCT)
were compared to 74 patients receiving MA conditioning. NMA reg-
imens included: ﬂudarabine/melphalan (FM), n= 25, ﬂudarabine/ara-
C/idarrubicin (FLAG-IDA), n= 22, ﬂudarabine/cyclophosphamide
with or without rituximab (FC/R), n= 18 and
cisplatin/ﬂudarabine/ara-C (PFA), n= 15. The MA group received IV
busulfan/cyclophosphamide (IV Bu/Cy), n= 43 and
Cy/TBI/thiotepa, n= 31. All patients had 6/6 matched sibling donors.
GVHD prophylaxis consisted of tacrolimus/methotrexate in all
patients except those receiving TBI, who received
cyclosporin/methotrxate (n=28/31) and CD8 depletion. Peripheral
stem cell grafts were used in 92% of the NMA group, 64% of the IV
Bu/Cy group, and 35% of the TBI group. Median age was 16 years
higher in the NMA group compared with the IV Bu/Cy and TBI
groups. Results: Cumulative incidence (CI) of acute GVHD was sig-
niﬁcantly higher in the TBI (74%) group compared with the NMA
(31%) and IV Bu/Cy (53%) group (p value <0.001 and 0.012, respec-
tively). Within the NMA regimens, the incidence was lowest in PFA
and FLAG-IDA. Only 22% of acute GVHD was grade III-IV, and
the distribution by grade was not significantly different between
groups. CI at 18 months was lowest for the TBI group (25% vs 56%
for IV Bu/Cy, and 43% for NMA, p=0.02), possibly reﬂecting a high-
er acute GVHD-related mortality in these patients. GVHD-related
death was higher in the TBI group (32%) compared with IV Bu/Cy
(6%) and NMA (9%) (p =0.01). Conclusions: The intensity of the
preparative regimen has an impact on the incidence of acute GVHD,
and in the case of TBI-base regimen on GVHD- related mortality as
well. Such a direct effect is not apparent for chronic GVHD.
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TUMOR NECROSIS FACTOR ALPHA BLOCKADE WITH INFLIXIMAB IN
THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD):
AN UPDATE
Couriel, D.R.; Hicks, K.; Ippoliti, C.; De Lima, M.; Donato, M.;
Cohen, A.; Andersson, B.; Hosing, C.; Giralt, S.; Champlin, R. UT
MD Anderson Cancer Center, Houston, TX
Infliximab is a chimeric human and murine antibody that
inhibits tumor necrosis factor (TNF) alpha, a central inflamma-
tory mediator in acute GVHD. In this study, we evaluate effica-
cy, infectious complications, relapse and survival following treat-
ment with infliximab in patients with acute GVHD. Fifty-nine
patients with acute GVHD undergoing allogeneic hematopoietic
stem cell transplant between 11/96 and 5/01 developed acute
GVHD following transplant or donor lymphocyte infusions.
Diagnoses included aplastic anemia (1), ALL (1), MDS/AML
(19), CML (14), myelofibrosis (1), CLL/NHL/HD (20), multi-
ple myeloma (2) and breast cancer (1). The majority of patients
received prophylaxis with tacrolimus/methotrexate (n= 57).
Forty-three patients (73%) had steroid-resistant acute GVHD,
and received infliximab after 48 hs of initiation of steroids.
GVHD was grade III-IV in 43 patients (73%) and I/II in 16.
Skin was involved in 32 patients, GI tract in 41 and liver in 18.
Infliximab was administered at 10 mg/kg/d once a week for a
median of 4 doses (range 1-8). The majority of patients received
ATG (34) or daclizumab (29) within 14 days of the administra-
tion of infliximab. Other salvage immunosuppressants included
MMF (7), azathioprine (1) and pentostatin (1). Responses
(CR/PR) were observed in 25/32 (78%) of patients with skin
GVHD, 32/41 (78%) of GI GVHD and 6/18 (33%) of liver
GVHD. Forty-seven patients (79%) experienced 108 document-
ed infections: 30 were caused by fungi, 36 were viral, 41 bacterial
and 1 mycobacterial. Ten of these 47 patients (21%) had infec-
tions caused by Aspergillus or Fusarium. The overall survival was
19% (95% CI 5.6-39), and the median survival was 5.7 months.
The leading cause of death was GVHD (57%) followed by
relapse (27.5%). Infliximab can induce a high response rate in
steroid-refractory acute GVHD. However, infectious complica-
tions and a high mortality rate are still major limitations to the
treatment of this condition.
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OMISSION OF DAY+11 METHOTREXATE AFTER MATCHED-RELATED
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
DOES NOT INCREASE THE RISK OF GRAFT-VS.-HOST DISEASE
Cutler, C.1,2; Antin, J.H.1,2 1. Dana-Farber Cancer Institute, Boston,
MA; 2. Brigham and Women’s Hospital, Boston, MA
Background: Graft-vs.-Host Disease (GVHD) after allogeneic
peripheral blood stem cell transplantation (PBSCT) is a major
cause of morbidity and mortality. Prophylaxis against GVHD gen-
erally consists of Cyclosporine/Tacrolimus with short course
Methotrexate (Mtx, 15 mg/m2 on day+1, 10 mg/m2 on days +3, +6,
+11), however, the 4th Mtx dose is often omitted due to severe
mucositis or other organ toxicity. After allogeneic BMT, omission
of the 4th Mtx dose has been shown both to increase and not inﬂu-
ence the rates of acute and chronic GHVD. Rates of chronic
GVHD are higher after PBSCT than BMT, therefore, we sought
to determine if omission of the day+11 Mtx would increase the risk
of GVHD after allogeneic matched-related PBSCT. Methods:
Using the PBSC arms of published trials comparing matched–relat-
ed allogeneic PBSCT to BMT, we performed a pooled analysis of
GVHD rates, comparing trials where standard Mtx dosing was used
with trials where alternate Mtx schedules or only 3 Mtx doses were
used. Results: Six randomized trials and 6 cohort studies involving
409 patients were included in the analysis. The rates of acute
GVHD (Gr. II-IV) were 42% and 46% for trials using standard and
incomplete Mtx prophylaxis (p=0.44, n=409). Severe acute GVHD
(Gr. III-IV) was not more common when incomplete Mtx was used
(15% for both groups, p=0.97, n=336). The rate of chronic GVHD
was 62% in both arms (p=0.98, n=351). 100 day mortality was no
different between groups but there was a trend towards increased
mortality after PBSCT (15.3 vs. 10.9%, p=0.26, n=322). Engraft-
ment times were not compared between arms. Conclusions: Four
doses of Mtx after allogeneic PBSCT did not offer enhanced pro-
tection against acute or chronic GVHD when compared with
abbreviated (3 doses) Mtx or alternate dosing schedules of Mtx. The
best dosing schedule for Mtx after PBSCT needs to be determined.
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MODULATION OF ANTIGEN PRESENTATION BY EXTRACORPOREAL
PHOTOPHERESIS IN CHRONIC GVHD
Foss, F.; Gorgun, G. Tufts New England Medical Center, Boston, MA
Extracorporeal photochemotherapy (ECP) has been shown to
be an effective therapy for patients with acute and chronic
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graft-vs-host disease (GVHD) following allogeneic bone mar-
row transplantation, but its biological mechanism is not under-
stood. We reported that clinical response to ECP was associat-
ed with normalization of CD4/CD8 ratios, increase in
CD3-/CD56+ NK cells and decrease in the number of CD80+
and CD123+ circulating dendritic cells (DC). To further eluci-
date the effects of ECP on antigen presentation and on activat-
ed lymphocyte subpopulations, we isolated DC from patients
prior to initiation of ECP and monthly while on therapy.
Immunophenotypic analysis demonstrated a preponderance of
CD80+/CD123+ DC1 cells in the GVHD patients prior to
ECP therapy. DC were differentiated in vitro and incubated
with autologus and allogeneic T cells in presence of tetanus
toxoid as an antigenic stimulus. Proliferation of both autologus
and allogeneic T cells was decreased by median of 84% (range
75-95%,) compared to baseline in 7 of 10 patients (P≤0.002)
after the two day cycle of ECP. The proliferation of autologus
T cells was 20-75% higher than allogeneic T-cells at baseline
in these patients (P≤0.007). After Staphylococcal enterotoxin-B
stimulation, Th1 cytokines (IFN-γ) were decreased 52% while
Th2 cytokines (IL-4, IL-10) were increased 65% in the 7
patients. This shift in cytokine secretion from Th1 to Th2,
along with modulation of the DC1/DC2 ratio, correlated with
clinical improvement in cutaneous and visceral cGVHD in the
treated patients. Our results demonstrate that ECP attenuates
ongoing alloreactivity in cGVHD by directly affecting antigen
presentation by DC, thereby shifting the Th1/Th2 balance in
favor of tolerance.
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CORRELATIONS BETWEEN IN VITRO DONOR ANTI-HOST AND IN
VIVO POST-HEMATOPOETIC STEM CELL TRANSPLANTATION TCR Vβ
UTILIZATION
Friedman, T.M.; Hopely, D.D.; Grosso, D.; McGuire, L.;
Flomenberg, N.; Korngold, R. Thomas Jefferson University, Philadel-
phia, PA
The major complications of allogeneic hematopoetic stem
cell transplantation (HSCT) include graft failure, opportunistic
infections, leukemic relapse and graft-versus-host disease
(GVHD). The incidence of the first three complications is
diminished by the presence of mature donor T cells in the
transplant inoculum. Unfortunately, the transplantation of
mature alloreactive donor T cells also directly induces the lat-
ter complication of acute GVHD, which can be directed
against either HLA or minor histocompatibilty antigen (miHA)
disparities. Efforts to deplete donor marrow inoculum of T
cells have been successful in minimizing the development of
disease but have been associated with increased leukemic
relapse. Thus, one approach to reduce the transplantation risk
factors would be to selectively deplete donor alloreactive T
cells in the SC inoculum while allowing the residual T cells to
provide some protection against infection and to support a
leukemia-specific GVL response. For a more targeted
approach, delayed lymphocyte infusion (DLI) of positively-
selected donor GVL-reactive T cells could be used weeks to
months post-transplant, if these elements were identifiable. In
this regard, TCR Vβ repertoire analysis by CDR3-size spec-
tratyping can be a powerful tool for the characterization of
alloreactive T cell responses. By using this analysis we com-
pared the donor T cell responses generated in vitro against
patient or third party PBL with those obtained in vivo follow-
ing allogeneic HSCT. The results showed that within a num-
ber of Vβ families there was a correlation between the in vitro
anti-patient and in vivo spectratype histograms, exhibiting
overlapping CDR3-size skewing. However, there were no cor-
relations in CDR3-size skewing between the in vitro anti-third
party and the in vivo spectratype histograms within any Vβ
family. Thus, in vitro spectratyping assays may then be useful
for predicting the alloreactive T cell responses involved in
inducing GVHD and could be used to guide Vβ family-deplet-
ed transplants.
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REMISSION INDUCED BY GEMTUZUMAB OZOGAMYCIN (MYLOTARG)
AND WITHDRAWL OF IMMUNOSUPPRESSION IN ALL WITH MYELOID
ANTIGEN EXPRESSION IN RELAPSE AFTER UNRELATED CORD
BLOOD TRANSPLANT
Gore, L.1,2; Hunger, S.P.1,2; Sievers, E.3; Giller, R.H.1,2;
Wei, Q.2; McGavran, L.1; Quinones, R.R.1,2 1. Univeristy of Col-
orado Health Sciences Center, Denver, CO; 2. The Children’s Hos-
pital, Denver, CO; 3. Fred Hutchinson Cancer Research Center,
Seattle, WA
Stem cell transplantation (SCT) is the preferred treatment for
refractory acute lymphoblastic leukemia (ALL). Unfortunately, dis-
ease recurrence is a common cause of failure after SCT. In patients
relapsing after SCT, donor lymphocyte infusion is a potential
option to induce graft-vs.-leukemia (GVL), however in unrelated
cord blood transplant (UCBT) this option is not currently available.
We report a 19 year-old female with pre-B ALL who relapsed 6
months after diagnosis. Aplastic, with disease control, she under-
went an uncomplicated myeloablative 4/6 UCBT and achieved
engraftment with full donor chimerism. She suffered a bone marrow
relapse on day +144, with cytogenetic evolution, new myeloid anti-
gen expression, and reduced donor chimerism. In order to promote
GVL, we discontinued immunosuppression and controlled her
leukemia with two doses of gemtuzumab ozogamycin (GO;
Mylotarg). She achieved leukemic cytoreduction and developed sys-
temic GVHD with skin and upper GI involvement. She subsequent-
ly entered complete remission (CR), and remains in CR3 with 99%
donor chimerism, now three months after inital GO therapy. This
treatment was completed as an out-patient, without complication or
evidence of veno-occclusive disease, and demonstrates the capacity
of targeted antibody therapy to induce remission while preserving a
GVL effect, even in the absence of donor lymphocyte infusion.
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THE RISK OF ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION IS NOT ALTERED WHEN FILGRASTIM OR SAR-
GRAMOSTIM IS USED FOR ENHANCEMENT OF ENGRAFTMENT
Ho, V.1; Mirza, N.Q.2; del Junco, D.3; Przepiorka, D.1 1. Baylor Col-
lege of Medicine, Houston, TX; 2. MedStats International, Houston,
TX; 3. University of Texas School of Public Health, Houston, TX
Filgrastim (G-CSF) and sargramostim (GM-CSF) are
hematopoietic growth factors with potent effects on neutrophil
recovery after autologous or allogeneic stem cell transplantation.
More recently, it has also been shown in animal models and in
normal human volunteers that these growth factors also induce
changes in in vitro measures of the immunoreactivity. We per-
formed a meta-analysis to determine if we could detect an effect of
G-CSF or GM-CSF on the risk of acute GVHD after allogeneic
transplantation. Twenty publications were identiﬁed in which data
were provided for cohorts receiving either growth factor or no
active drug. These included 11 prospective randomized studies, 8
retrospective cohort studies and 1 case-control study comprising a
total of 1311 patients. The publication types were heterogeneous
with regard to growth factor dose-schedule, patient age group,
diagnosis, donor histocompatibility, stem cell source and GVHD
prophylaxis, although within publications, comparative groups
were generally balanced. The summary risk ratios for acute
GVHD are provided in the table. No signiﬁcant effect of growth
factor on grades 2-4 or 3-4 GVHD was detected by meta-analysis.
This was not due to lack of biological activity of growth factor in
these patients, since the time to neutrophil recovery was shortened
by growth factor use in all studies. We conclude that the risk of
87B B & M T
Poster Presentations - Session I
acute GVHD after allogeneic hematopoietic stem cell transplanta-
tion is not altered signiﬁcantly by ﬁlgrastim or sargramostim.
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INFLIXIMAB FOR THE TREATMENT OF STEROID-REFRACTORY
ACUTE GVHD
Jacobsohn, D.A.; Hallick, J.; Anders, V.; Vogelsang, G.B. Johns Hop-
kins, Baltimore
The survival of patients with steroid-refractory grade III-IV
acute GVHD is usually in the 20% range. New agents are clearly
needed. TNF-α is an important mediator in GI and skin GVHD.
We have treated 5 acute GVHD patients with inﬂiximab, an anti-
TNF-α monoclonal antibody. The majority of these patients were
extremely ill with voluminous diarrhea as well as infections com-
plicating their acute GVHD. Four patients with advanced GVHD
were treated at a dose of 10mg/kg weekly to assess toxicity and
response. An additional patient who had relapsed post-transplant
received 5mg/kg weekly to treat refractory skin disease. Two
patients had a complete response and 1 patient had a partial
response. We conclude that the drug was well tolerated. In two
patients, infectious complications worsened. It is impossible to
attribute this to inﬂiximab, prior therapy, or underlying GVHD.
Earlier therapy needs to be investigated to ascertain the role of
this drug in the therapy of GVHD.
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RAPAMYCIN FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST
DISEASE
Johnston, L.J.1; Shizuru, J.S.1; Stockerl-Goldstein, K.E.1; Stuart, M.1;
Blume, K.G.1; Negrin, R.S.1; Chao, N.J.2 1. Stanford University,
Stanford, CA; 2. Duke University, Durham, NC
Chronic graft-versus-host disease (CGVHD) occurs in ≥ 40%
of allogeneic hematopoietic cell transplantation (HCT) recipi-
ents with control requiring years of immunosuppression. Exten-
sive CGVHD requires prolonged prednisone (PSE). We con-
ducted a phase II trial in CGVHD patients with the combination
of rapamycin and calcineurin inhibitors [cyclosporin (CsA) or
FK506]. Our goals were to control CGVHD and spare PSE. Six-
teen patients received rapamycin with CsA (12) or FK506 (4) and
PSE. Fourteen patients had extensive CGVHD. The onset of
CGVHD was de novo in eight, quiescent in six and progressive
in two patients. Eleven patients were tapering CsA/FK506 or
CsA/FK506 and PSE at the onset of CGVHD. Rapamycin was
begun as second (10) or third (6) line therapy after CsA/FK506
and PSE. The median maximum dose of PSE prior to rapamycin
was 0.5 mg/kg/d (0.1-2 m/kg/d). With a median follow-up of 10
(7-29) months, nine of the sixteen patients had improvement of
CGVHD. One patient discontinued all systemic immunosup-
pression, three were tapering PSE and/or CsA/FK506 and one
was on stable doses of all agents. Four patients successfully dis-
continued PSE with one requiring reinstitution of PSE after 7
months and rapid resolution of oral and liver CGVHD. Two of
nine patients began photopheresis for progressive sclerodermal
CGVHD after initial response/stability on rapamycin. Both
patients progressed while off PSE but on stable rapamycin and
FK506/CsA doses. Seven patients were removed from study: 3-
serum creatinine (Cr) >3.0 mg/dl, 2-hemolytic uremic syndrome,
1-headache, 1-relapsed malignancy. Toxicities in all patients
included: 6-platelet count <100,000/ul, 8-serum Cr > 2.0 mg/dl,
6-infections (4 oral HSV, 1 disseminated varicella zoster, 1 cryp-
tosporidium/salmonellosis/perirectal abscess). 15/16 were alive
with one death from relapsed malignancy. In conclusion,
rapamycin is an effective therapy for refractory CGVHD. The
toxicities of rapamycin in combination with calcineurin
inhibitors and prednisone are significant and warrant close
patient observation.
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VACCINATION AGAINST SYNGENEIC MYELOID LEUKEMIA CELLS PRIOR
TO SYNGENEIC BONE MARROW TRANSPLANTATION (BMT) PROLONGS
RECIPIENT SURVIVAL IN CYTOTOXICALLY DEFECTIVE MICE
Jones, M.; Williamson, T.M.; Levy, R.B. University of Miami, Miami, FL
This study examined the effect of vaccination against myeloid
leukemia cells prior to a syngeneic BMT and subsequent tumor
challenge in wild type (wt) and cytotoxically single defective (csd)
recipients. To determine whether anti-tumor immunity generated
prior to BMT could inhibit tumor growth in the post-transplant
period, a c-myc retrovirus-transformed myeloid leukemia line
(MMB3.19) generated from a B6 mouse was employed. The
MMB3.19 line was shown by others to express Mac-1/2, LFA-1,
Fas, as well as MHC class I and II cell surface molecules. Korn-
gold et.al. (Transpl. 1994) reported that 1x105 tumor cells injected
into irradiated (8.5Gy TBI) B6 mice one day post syngeneic BMT
resulted in 100% mortality by ~35 days. In this study, B6-wt, B6-
perforin knock out (B6-pko) and B6 FasL defective (B6-gld) mice
were inoculated with 1x107 irradiated MMB3.19 i.p. 4 weeks prior
to BMT. One day prior to BMT, mice were irradiated (8.5Gy)
and the following day injected with 2x106 TCD syngeneic mar-
row. On D+1 post-BMT, vaccinated and unvaccinated mice
received an ip tumor challenge of 1x105 viable MMB3.19 cells.
Unvaccinated mice died by D+24 post-transplant [MST (days):
B6-wt, 11.0; B6-pko, 4.3; B6-gld, 14.0]. Mice vaccinated prior to
transplant survived significantly longer than unvaccinated mice
[MST: B6-wt, >44; B6-pko, >33.0; B6-gld, >39.8]. Although MST
increased in vaccinated mice, tumor ascites and/or lesions at the
injection site occurred. Tumor presence in B6-gld and B6-pko
mice was observed ~3 weeks post-BMT vs. ~5 weeks post-BMT in
B6-wt mice. These findings indicate that a radio-resistant anti-
tumor response was generated in all vaccinated mice post-BMT.
CSD mice were not protected as well as wt mice, indicating that
both pathways contribute to the radio-resistant anti-tumor
response. In total, these results suggest the presence of autologous
immune cells in the immediate transplant period maintain the
capacity to inhibit subsequent tumor growth.
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CONTRASTING DISEASE SEVERITY ACROSS RELATED MINOR HISTO-
COMPATABILITY ANTIGEN BARRIERS:EVIDENCE OF SIMILAR PERIPHER-
AL T CELL ALLORESPONSES WITHOUT PROGRESSION TO ACUTE GVHD
Jones, S.C.; Friedman, T.M.; Murphy, G.; Korngold, R. Thomas Jef-
ferson University, Philadelphia, PA
CXBE recombinant inbred mice express a subset of the
miHA repertoire expressed by BALB.B mice. When lethally
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irradiated and transplanted with H2b-matched C57Bl/6 (B6)
T-cells along with bone marrow cells, both strains succumb
to acute GVHD. Purified B6 CD4+ T-cells however, are
capable of mediating acute disease only in BALB.B recipients.
To begin to study the contrasts in the CD4 response, CFSE
labeled B6 T-cells were transferred into lethally irradiated
recipients; three to five days later splenocytes were studied
for the size of the responding CD4+ T-cell population and
the alloreactive B6 CD4+ T-cell precursor frequency against
the BALB.B or CXBE miHA pools were calculated. Interest-
ingly, the frequency of naive B6 CD4+ T-cells capable of
responding against either recipient strain was not significant-
ly different. Morphological study has revealed a similar
amount of CD4+ T-cell infiltration in the lingual epithelium
of both BALB.B and CXBE recipients. However, significantly
more CD4+ IELs were observed in the small bowel of
BALB.B vs CXBE recipients. These data strongly suggested
qualitative differences between the two alloresponses to
explain the stark contrast in GVHD severity. To further
study this, we selectively transferred B6 CD4+ T-cells utiliz-
ing Vβ families found involved either specifically in the anti-
BALB.B response (Vβ’s 2&11) or Vβ families involved in
both strain combinations (Vβ’s 10&12) into lethally irradiat-
ed recipients. We observed acute disease in BALB.B recipi-
ents receiving either Vβ group, contrasted by only minimal
weight loss observed in CXBE recipients of Vβ’s 10&12.
These results suggest that peripheral CD4+ T-cell involve-
ment in an alloresponse as well as specific tissue infiltration
need not result in clinically significant GVHD. Understand-
ing the pathologic significance of the homing of responding
T cells to specific GVHD target tissues should give us first
hand insight into the events leading to CD4 mediated, miHA
driven acute GVHD.
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LPAM IS AN IMPORTANT HOMING INTEGRIN ON ALLOREACTIVE T
CELLS IN THE DEVELOPMENT OF INTESTINAL GRAFT-VERSUS-HOST
DISEASE
Kirovski, A.D.; Feinman, J.; Alpdogan, O.; Schmaltz, C.;
Muriglan, S.J.; Greenberg, A.; Lewis, L.; van den Brink, M. Memori-
al Sloan Kettering Cancer Center, New York, NY
LPAM (Lymphocyte Peyer’s patch adhesion molecule),
alpha4 beta7, is a member of the integrin family, which is
responsible for broad array of cell-cell and cell- extra cellular
matrix interactions. Through the interaction with receptor
for mucosal addressin cell adhesion molecule on high
endothelial venules in mucosal lymphoid organs, LPAM
mediates T and B cell homing into the GALT (gut associated
lymphoid tissues). Therefore, we hypothesized that LPAM
expression on alloreactive T cells was important for the
development of intestinal Graft-versus-Host
Disease(GvHD). We used a MHC-minor antigen mis-
matched murine allogeneic bone marrow transplantation
(BMT) model and compared the expression of LPAM in
spleen, skin and gut of normal mice, or recipients of an allo-
geneic bone marrow transplantation with or without GvHD.
We detected increased expression of LPAM on CD4+ and
CD8+ donor T cells in the intestinal mucosal of the recipi-
ents with GvHD. To determine a functional role for LPAM
on alloreactive T cells we separated LPAM+ donor T cells
from LPAM- donor T cells by flow cytometric cell sorting
and analyzed their GvHD activity in vivo. When we com-
pared recipients of LPAM- donor T cells to recipients of
LPAM+ T cells we found significant decrease in mortality,
morbidity, gut GvHD, and weight loss. We are currently
assessing the Graft-versus-Tumor (GvT) activity of LPAM+
and LPAM- selected populations of donor T cells. These
studies appear to support the hypothesis that LPAM is an
important homing integrin for alloreactive T cells to enter
the intestinal tissues and that strategies to inhibit LPAM (for
example by neutralizing antibodies) could decrease the inci-
dence of intestinal GvHD.
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FUNCTIONAL CHARACTERIZATION OF EBV PEPTIDE-SPECIFIC T LYM-
PHOCYTES ISOLATED WITH MHC TETRAMERS
Koehne, G.; Leiner, I.; Williams, R.Y.; Ferguson, T.L.; Pamer, E.G.;
O’Reilly, R.J. Memorial Sloan-Kettering Cancer Center, New York, NY
Generation of peptide-specific T-cells is an important first
step for adoptive immunotherapy. Sorting of immunodomi-
nant, peptide-specific T-cells with MHC-class I tetramers is a
potential method for rapidly selecting desired T-cell popula-
tions for infusion into recipients. We analyzed EBV-specific T-
cell lines with HLA-B8 tetramers complexed with peptides
derived from EBNA 3a (QAKWRLQTL) or BZLF 1 (RAK-
FKQLL), and HLA-A2 tetramers complexed with peptides
derived from EBNA 3c (LLDFVRFMGV) or BMLF 1
(GLCTLVAML). Over a 3-4 week period, CD8+ T-cells spe-
cific for the latent EBNA 3a or EBNA 3c peptides increased
from 0.2% - 0.4% at the initiation of culture to 6 - 8%, as
determined by tetramer staining. In contrast, CD8+ T-cells
specific for lytic BZLF 1 or BMLF 1 peptides increased to 20 -
45%. We purified CD8+ tetramer+ T-cells specific for latent or
lytic epitopes by FACSorting and analyzed their effector func-
tions. CD8+ tetramer+ cells did not lyse or produce intracellular
IFN-γ upon stimulation with autologous EBV BLCL.
Tetramer sorted T-cells, however, did lyse autologous EBV
BLCL pulsed with relevant peptides in a concentration
dependent manner. In one representative example, lysis of the
autologous EBV BLCL increased from 0% to 19%, 25% and
33% after pulsing with 0, 0.1, 1.0 or 10 µg/ml of EBNA 3a
peptide. The percentage of IFN-γ-producing CD8+ cells
increased from 0.5% to 10.1%, 22.0% and 35.2% after stimula-
tion with BLCL pulsed with these graded concentrations of
peptide. Because EBV-specific CTL lines have multiple pep-
tide-specificities, CD8+ tetramer- cells maintained the capacity
to lyse the autologous EBV BLCL (12% lysis at all peptide-
concentrations), and 2.4% of the CD8+ cells produced IFN-γ at
all concentrations of peptide, indicating the depletion of the
peptide-specific population from this fraction. These results
suggest that MHC-tetramer staining, while a feasible method
for isolating EBV-specific CD8 T-cells, may down-regulate
effector functions of sorted CTL.
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REGULATION OF CYTOTOXICALLY DOUBLE DEFECTIVE CD8+
DONOR T CELL EXPANSION FOLLOWING BMT: IMPLICATIONS FOR
FRATRICIDAL AICD VIA CD95L AND/OR PERFORIN IN ALLOGENEIC
RECIPIENTS
Marks, L.; Levy, R. University of Miami School of Medicine, Miami, FL
We have previously reported that donor B6-CD8 T cells
lacking CD95L and perforin expand to high levels upon trans-
fer into MHC-matched irradiated (9.0 Gy) recipients. This is
in marked contrast to the typical pattern of expansion and con-
traction of B6-wt CD8 T cells following allogeneic transplan-
tation. We hypothesize that T cells lacking CD95L and per-
forin (cytotoxically double defective – cdd) do not undergo
appropriate regulation due to inefficient activation-induced
cell death (AICD). Host cells in this model system do not
appear to possess the capacity to inhibit donor B6-cdd CD8
cell proliferation. To address these issues, B6-cdd T cells were
co-transplanted with either B6-wt SPL/LN or B6-nu/nu
SPL/LN cells to determine whether B6-cdd T cells can be
coordinately regulated in the presence of exogenous congeneic
populations within an allogeneic host. Notably, B6-cdd donor
CD8 cells alone, or when combined with B6-nu/nu SPL/LN
cells exhibited profound amplification. In contrast, B6-wt
SPL/LN cells demonstrated the ability to curtail B6-cdd CD8
cell expansion in the allogeneic recipient. Total SPL/LN num-
bers also paralleled the cell numbers within the CD8 compart-
ment. These findings corroborate prior observations revealing
massive proliferation of B6-cdd T cells following transfer into
allogeneic BMT recipients. Based on the ability of B6-wt but
not B6-nu/nu SPL/LN cells to regulate cdd CD8 T cell
expansion, we propose that syngeneic B6-wt T cells (present in
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B6-wt but not B6-nu/nu SPL/LN) have the capacity to inhibit
accumulation of large numbers of B6-cdd T cells, perhaps
through fratricidal killing following the T cell expansion
phase. We intend to pursue these findings by determining
which T cell subsets and mechanisms are required to constrain
abnormal B6-cdd CD8 expansion. These answers may provide
clues to what mechanism(s) and cells are responsible for pre-
venting CD8 cell accumulation during an ongoing immune
response.
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ANALYSIS OF DONOR CD4+ T CELL ALLOREACTIVE CLONES AND
THEIR CORRELATION WITH GVHD
Michalek, J.1; Collins, R.H.1; Hill, B.J.2; Douek, D.C.2; Vitetta, E.S.1
1. University of Texas Southwestern Medical Center, Dallas, TX;
2. NIH Vaccine Research Center, Bethesda, MD
After allogeneic stem cell transplantation (SCT), GVHD can
be initiated by major and minor histocompatibility antigens on
cells from the recipient, which stimulate an alloresponse by
donor T cells. The alloresponse is usually oligoclonal. Howev-
er, reports describing the behavior of alloreactive clones after
SCT, their quantification and correlation with the clinical
occurrence of GVHD are limited. In this study, donor
GVHD-specific CD4+ T cell clones arising in the recipient
were characterized after SCT. Changes in frequency of these
clones were then correlated with clinial outcome. Donor CD4+
T cells activated in a one-way mixed lymphocyte culture with
irradiated recipient cells were sorted on a flow cytometer and
their T cell receptor beta (TCRB) genes were analyzed. A
cDNA library was prepared from the sorted cells and 40-50
bacterial colonies were analyzed by direct sequencing of TCRB
CDR3 regions. Clone-specific primers were then constructed
to allow follow-up post-transplant using quantitative real-time
PCR. Of the 4 patient/donor pairs studied, 3 were HLA
matched, and one had a single mismatch at HLA DR. The
patient with the HLA DR mismatch developed manifestations
of acute GVHD with skin rash, fever, and thrombotic throm-
bocytopenic purpura on day 51 and died of complications of
actue GVHD 107 days after the transplant. Two other patients
developed acute GVHD. In all 3 patients with clinical GVHD,
the presence of alloreactive clone(s)correlated closely with
GVHD and inversely correlated with immunosuppressive ther-
apy of GVHD.
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SEROLOGIC RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY ANTI-
GENS FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION
Miklos, D.; Guo, L.; Hochberg, E.; Viatte, S.; Zorn, E.; Neuberg, D.;
Alyea, E.P.; Antin, J.; Soiffer, R.; Ritz, J. Dana-Farber Cancer Insti-
tute, Boston, MA
Males who have undergone sex-mismatched allogeneic bone
marrow transplantation are at high risk for graft-v-host dis-
ease (GVHD). In these patients, previously identified H-Y
minor histocompatibility antigens are known to be targets of
cytotoxic T-cells (CTL) in patients with GVHD. H-Y anti-
gens are peptides derived from proteins encoded on the Y
chromosome that are presented by major histocompatibility
antigen (MHC) class I and class II molecules. We hypothe-
sized that minor histocompatibility (mHA) immunogenicity
results in a coordinated response involving both T and B-cell
responses. To test the humoral response, we expressed full-
length known H-Y antigens (DBY and UTY), and western
blotted these lysates with both normal donors and BMT
patient serum diluted 1:500. More than 25% of male patients
with female donors demonstrated serologic responses to these
H-Y antigens. In contrast, only one sex-matched male patient,
and no normal male donors exhibited H-Y serologic respons-
es. Thus H-Y antigen serologic recognition occurs specifically
in male patients with female donors. While both normal
female donors and female patients have H-Y serologic
responses, our data suggests these may be due to other modes
of H-Y antigen exposure such as male pregnancy or blood
transfusions.
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LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH DACLIZUM-
AB FOR ACUTE GRAFT-VS-HOST DISEASE
Perales, M.; Boulad, F.; Castro-Malaspina, H.; Jakubowski, A.;
O’Reilly, R.J.; Papadopoulos, E.; Prasad, V.K.; Small, T.N.;
Young, J.W.; Kernan, N.A. Memorial Sloan-Kettering Cancer Center,
New York, NY
Daclizumab (Zenapax, ZPX) is a humanized monoclonal IgG1
that binds the α chain (p55 subunit) of the high affinity IL-2
receptor (CD25) and blocks the action of IL-2. It has been
shown to have activity in the treatment of Acute Graft-vs-Host
Disease (GVHD). Use of ZPX, however, appeared to be associ-
ated with an increased risk of infection. To further investigate
the risk of ZPX treatment, we performed a retrospective review
of sixty-three patients who underwent an allogeneic bone mar-
row transplant (BMT) from January 1993 though June 2000 and
were treated with ZPX for acute GVHD. The median age of
patients was 27 (range, 1-57 years). Forty-six patients received
bone marrow, 4 blood stem cells, 11 both marrow and stem cells,
1 cord blood, and 1 a non-myeloablative BMT. Thirty-seven
patients had HLA-matched donors, and 26 had alternative
donors. Forty-nine patients required ZPX for GVHD developed
after initial BMT. The remainder was treated after a second
BMT or a marrow boost. The median number of ZPX doses
given was 5 (range 1-23), with 44% patients receiving 5 treat-
ments. GVHD was assessed at baseline and day 43. Most
patients (77.5%) had an improvement in their GVHD score, and
only a minority (2.5%) had a worsening of the GVHD. Oppor-
tunistic infections developed in 28 patients and included CMV
(22), EBV-LPD (5) and toxoplasmosis (1). Forty-seven patients
(75%) died following treatment with ZPX. The causes of death
were infection (62%), GVHD (30%) and progressive disease
(13%). Infectious causes of death included sepsis (17), pneumo-
nia (6), EBV-LPD (3), CMV (2), brain abscess (2), disseminated
HSV (1) and disseminated toxoplasmosis (1). Although ZPX is
active in the treatment of GVHD, it is associated with significant
morbidity and mortality due to infectious complications. Careful
patient selection and close monitoring is recommended when
using ZPX.
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HAPLOIDENTICAL TRANSPLANTS WITH KIR LIGAND INCOMPATIBILI-
TY IN THE GVH DIRECTION AFFORD STRIKING SURVIVAL ADVAN-
TAGE IN AML
Ruggeri, L.; Capanni, M.; Urbani, E.; Tosti, A.; Perruccio, K.;
Aversa, F.; Martelli, M.F.; Velardi, A. Perugia University School of
Medicine, Perugia, Italy
In haploidentical transplants, when KIR ligand incompatibil-
ity is in the GvH direction, the post-grafting NK repertoire
contains donor-vs-recipient alloreactive NK clones which kill
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host targets, including myeloid leukemia (Ruggeri, Blood
1999). The impact of this phenomenon was evaluated in 92
transplanted bad-risk acute leukemia patients with 1-8 year
follow-up. Transplants were divided into two groups. In the
first (n=58), there was no (HLA-C 1, HLA-C 2, HLA-Bw4
allele) KIR ligand incompatibility in the GvH direction and,
indeed, only 1/58 donors possessed anti-recipient NK clones.
In the second (n=34), there was KIR ligand incompatibility in
GvH direction, and all 34 donors possessed NK clones allore-
active against recipient target cells. Crucial variables for
engraftment and/or GvHD/GvL, status of disease at trans-
plant, conditioning regimen, number of stem and T cells in
the graft, were the same in the two groups. In the absence of
KIR ligand incompatibility in the GvH direction, rejection
and GvHD rates were 15.5% and 13.7%, respectively. In the
presence of KIR ligand incompatibility in the GvH direction,
graft rejection and GvHD rates were both 0% (P<0.01).
Moreover, while in the absence of GvH KIR ligand disparity
relapses occurred in 10/37 AML patients (with a 60% proba-
bility of relapse at 5 years of), zero relapses occurred in 20
AML patients transplanted from donors with KIR ligand
incompatibility in the GvH direction (P<0.002). Evidence
from mouse models shows alloreactive NK cell kill myeloid
leukemia, ablate the host immune system, and eliminate host
APCs triggering GvHD (Ruggeri, ASH 2001). The combined
action of these effects impacts dramatically on the event-free
survival of AML patients, which was 10% in the absence of
KIR ligand incompatibility in the GvH direction, vs 60% in its
presence (P<0.001). Choosing donors with KIR ligand incom-
patibility in the GvH direction offers a striking advantage for
survival.
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AN ATTEMPT TO PREVENT MORTALITY FROM ACUTE GVHD IN
80 MATCHED RELATED DONOR STEM CELL RECIPIENTS BY
ADDING LOW DOSE ANTITHYMOCYTE GLOBULIN TO A MTX/CSA
REGIMEN
Russell, J.A.; Chaudhry, A.M.; Fibich, C.; Stewart, D.; Gluck, S.;
Morris, D.; Ruether, D.; Parameswaran, R.; Brown, C. Alberta BMT
Program, Calgary, AB, Canada
We have studied a GVHD prevention regimen comprising
rabbit antithymocyte globulin (ATG, Thymoglobulin, Sang-
stat) 4.5mg/kg over 3 days completing on day -1 or 0,
cyclosporin A and “short” methotrexate with folinic acid.
Eighty adults received this regimen after conditioning with flu-
darabine 50mg/m2 on days -6 to -2 plus busulfan on days -5 to
-2 inclusive. Seven received qid BU lmg/kg PO, 2 had
0.8mg/kg IV qid (Busulfex, Orphan Medical) and 71 IV BU 3.2
mg/kg daily. Twelve ALL pts had additional TBI 200cGy x 2.
The median age was 43 (range 17-64), 11pts received BM, 68
blood cells and 1 both cell sources. Thirty-eight pts (48%) had
low - risk malignancy, ALL/lymphoblastic lymphoma (7) or
AML (21) in CR1 and CML in CP1 (10). Eighteen pts had
advanced acute leukemia, ALL (2), biphenotypic (2), CML BC
(1) or AML either de novo relapsed/refractory or progressing
from MDS. The remaining 24 pts had CLL (4, one with
Richter’s syndrome), NHL (9), HD (2), CML AP (2) and one
each with ALL CR2, AML CR2, CML CP2, hypereosinophilic
syndrome, prolymphocytic leukemia, MDS and MM. The inci-
dence of acute GVHD grade II-IV was 15±5%, grade III 5±3%
with no deaths from this cause. Actuarial incidence of chronic
GVHD at 2 years is 39±8%. There were three non-relapse
deaths and no cases of PTLD. With median follow-up of 16
months (range 2-34) projected transplant-related mortality at
one and two years is 5±3%. Projected disease-free and overall
survival at two years is 75 ±9% and 93±5% for low-risk dis-
ease, 22±10% and 39±11% for advanced acute leukemia and
77±9% and 81±9% for other disease respectively. This regi-
men incorporating low-dose ATG is relatively well tolerated
and seems effective at preventing death from acute GVHD
without significantly increasing the risk of opportunistic infec-
tion or PTLD.
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TRAIL AS A T CELL CYTOLYTIC PATHWAY EFFECTOR CRITICAL TO
THE GRAFT-VERSUS-LEUKEMIA RESONSE
Schmaltz, C.1; Alpdogan, O.1; Rotolo, J.A.1; Muriglan, S.J.1;
Kappel, B.J.1; Ongchin, J.N.1; Greenberg, A.S.1; Crawford, J.M.2;
Yagita, H.3; Walczak, H.4; Peschon, J.J.5; van den Brink, M.R.1
1. Memorial Sloan-Kettering Cancer Center, New York, NY; 2. Uni-
versity of Florida, Gainesville, FL; 3. Juntendo University School of
Medicine, Tokyo, Japan; 4. German Cancer Research Center, Heidel-
berg, Germany; 5. Immunex Corporation, Seattle, WA
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the tumor necrosis-factor (TNF) super-
family. In soluble form it exhibits substantial and speciﬁc tumori-
cidal activity in vitro and in vivo. In its membrane-bound form
TRAIL has been shown to have a role in tumor surveillance by
liver NK cells, however, its role on T cells remains largely
unknown. We used recently generated TRAIL-deﬁcient mice in
clinically relevant experimental bone marrow transplantation
(BMT) models to study the role of TRAIL on alloreactive T cells
in graft-versus-host-disease (GvHD) and graft-versus-leukema
(GvL) activity. We ﬁrst demonstrated that TRAIL is expressed in
vitro and in vivo on allo-reactive T cells, stimulated with IFN-α.
T cells deficient in TRAIL (TRAIL-/-) showed intact in vitro
proliferation and in vivo expansion as well as similar intracellular
cytokine profiles upon allogeneic stimulation. In three different
MHC-matched and -mismatched allogeneic BMT models we
found that the addition of wt or TRAIL-/- T cells to the graft
resulted in comparable levels of graft-versus-host disease. There
was no significant difference in histopathological evidence of
intestinal/liver target organ damage between recipients of wt and
of TRAIL-/- T cells. Graft-versus-leukemia activity however was
signiﬁcantly impaired when TRAIL-/- T cells were used in these
models in combination with TRAIL-sensitive tumor cells: using
32Dp210 (CML) leukemia cells in (B6 x C3H)F1 recipients medi-
an survival decreased from 51 days (wt T cells) to 32 days
(TRAIL-/- T cells) (p=0.003). Similar results were obtained in a
second GVL model with p815 mastocytoma cells. We conclude
that in our murine models TRAIL has an important role in GVL
activity mediated by donor T cells, but is not an important media-
tor of GVHD. These data suggest that future therapeutic strate-
gies to enhance TRAIL-mediated graft-versus-leukemia activity
could decrease the relapse rate after BMT without exacerbation
of GVHD.
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RITUXIMAB FOR AMPLIFICATION OF GRAFT-VERSUS-TUMOR
EFFECTS AFTER ALLOGENEIC TRANSPLANTATION FOR AGGRESSIVE
LYMPHOMA
Shimoni, A.; Hardan, I.; Avigdor, A.; Yeshurun, M.; Ben-Bassat, I.;
Nagler, A. Chaim Sheba Medical Center, Tel-Hasomer, Israel
High-dose chemotherapy and autologous stem cell transplanta-
tion have an established role in patients with chemo-sensitive
relapse of aggressive lymphoma but have only limited success
when attempted at refractory or progressive stage. Rituximab
(anti-CD20 monoclonal antibody) has been shown to be effective
therapy of aggressive lymphoma especially when combined with
combination chemotherapy. This study was designed to explore
the anti-tumor effect of rituximab given after allogeneic transplan-
tation. Seven patients at median age 50 (25-64) were included in
the study. All had large-cell lymphoma in progressive chemo-
refractory stage after a median of 3 prior therapies (2-6). All were
given allogeneic transplantation from an HLA-matched sibling.
Six were conditioned with BEAM, and one, who had a prior autol-
ogous transplant, was given non-myeloablative conditioning con-
sisting of fludarabine and busulfan. All patients engrafted. Five
patients were given rituximab (375 mg/m2 x 4 weekly doses) at 2-3
months after transplant, one is currently been treated and one
patient died of VOD 3 weeks post-transplant. At median follow-
up of 6 months (1-14) 5 of 6 evaluable patients are alive and dis-
ease-free. Five patients have developed GVHD (2 acute, 3 chron-
ic) that was mild and easily controlled in all.
Graft-versus-lymphoma effect was documented in 3 patients by
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continuous regression of active lymphoma persisting after the
transplant with the onset of GVHD and rituximab therapy. Two
patients are in remission more than 1 year post-transplant, a
remarkable outcome considering the refractory nature of their
underlying malignancy. Interestingly, the potent graft-versus-lym-
phoma effects were disproportionate to the mild GVHD. We
speculate that rituximab amplifies GVT effects. It may induce
donor cell ADCC or synergies with allogeneic responses in induc-
ing apoptosis of lymphoma cells. Rituximab may have also limited
the severity of GVHD. Rituximab merits further study as a means
to improve outcome after allogeneic transplantation for aggressive
lymphoma.
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GRAFT VS. HODGKIN’S DISEASE (HD): REDUCED INTENSITY TRANS-
PLANT IN A CHEMOTHERAPY-REFRACTORY PATIENT
Stein, J.1; Goshen, Y.1; Woolfrey, A.E.2; Yaniv, I.1 1. Schneider Chil-
dren’s Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv
University, Petach Tikva, Israel; 2. Fred Hutchinson Cancer Research
Center, Seattle, WA
Autologous stem cell transplantation (SCT) is a widely used
modality in the treatment of relapsed HD, but allogeneic SCT is
infrequently performed in these cases because of its inherent toxi-
city and limited proof that a graft vs. HD effect exists. We report
success of graft vs HD in curing an otherwise unsalvagable patient
with HD. An 8 year old boy with hypo- gammaglobulinemia and
bronchiectasis, presented at age 4 with stage IIB HD (nodular
sclerosis subtype). Three cycles of COPP/ABVD and two cycles
of MOPP yielded a partial response, and he subsequently devel-
oped relentlessly progressive disease. He tolerated third-line
chemotherapy poorly with frequent life-threatening infections and
minimal disease response. Massive mediastinal and abdominal
lymphadenopathy eventually led to respiratory distress. In
November 2000 he underwent bone marrow transplantation (total
nucleated cell dose 3.56 x 10E8/kg) from his HLA identical sister
after preparation with Fludarabine, low-dose (200 cGy)total body
irradiation, Cyclosporine A (CSA) and Mycophenolate mofetil
(MMF) (Seattle Regimen). Acute graft vs. host disease of the skin
(Stage 1) and intestine (Stage 1) ensued but responded to oral
steroids and continuation of MMF and CSA. Chimerism, assessed
by FISH analysis revealed 8% XX cells on day +9, 66% XX cells
on day +21 and 99% XX cells on day +60. Disease response was
prompt (beginning on day +6) and the patient now has no signs of
disease one year after transplant. In our patient, reduced intensity
allogeneic SCT led to cure of refractory HD,probably through
induction of a graft vs. HD effect.
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EX VIVO L-LEUCYL-L-LEUCINE METHYL ESTER TREATED ALLOGENE-
IC LYMPHOCYTES ARE ABLE TO MOUNT IN VIVO PROLIFERATIVE
RESPONSES WITHOUT GVHD IN A LETHALLY IRRADIATED HAP-
LOIDENTICAL MURINE MODEL
Varadi, G.; Jones, S.C.; Flomenberg, N.; Korngold, R. Thomas Jeffer-
son University, Philadelphia, PA
L-leucyl-L-leucine methyl-ester (LLME) induces apoptosis of
granzyme positive NK cells, monocytes, granulocytes, the majori-
ty of CD8+ T cells, and a fraction of CD4+ T cells, while leaving
intact the FAS-ligand positive CD4+ subpopulation. To test the
possibility that LLME-treated T cells would induce less severe
GVHD in a fully haploidentical murine transplant model, we
injected ex vivo LLME- and Mock-treated (B6xDBA/2)F1 T cells
along with bone marrow cells into (B6xCBA)F1 lethally irradiated
mice (10 Gy). The recipients of LLME-treated lymphocytes had
100% survival, as compared to 0% of those mice that received
Mock-treated lymphocytes, succumbing to GVHD. We hypothe-
sized that if LLME-treated T cells could still respond to alloanti-
gen perhaps at a lower level, they may still be able to mount effec-
tive GVL responses by either cytokine mediation or via Fas-ligand
system. Effective retention of GVL capacity had been previously
observed in a delayed donor infusion model. To investigate in vivo
proliferative potential, we labeled ex vivo LLME- and Mock-
treated (B6xDBA/2)F1 splenocytes with carboxy-ﬂuorescein-diac-
etate-succinimidyl-ester (CFSE), and transplanted them (4 x 107)
into lethally irradiated (B6xCBA)F1 recipients. By this approach,
the division history of a cell population can be traced, analyzed by
ﬂow-cytometry, and ultimately the alloreactive precursor frequen-
cy can be extrapolated. The results indicated that both LLME-
and the Mock-treated CD4+,CD25+ donor cells were capable of
in vivo proliferative alloresponses. However, the frequency of
reactive LLME-treated cells was slightly smaller in number than
that of the mice receiving the Mock-treated cells. Thus, it appears
that despite the elimination of granzyme-positive effector cells
and a decreased incidence and severity of GVHD, remaining T
cells are still able to mount some level of alloreactive proliferative
responses. These responses may be important for anti-leukemic
activity, and further in vivo testing will examine this question in a
model using a myeloid leukemia cell line.
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TUMOR NECROSIS FACTOR ALPHA BLOCKADE IN THE TREATMENT
OF GRAFT-VERSUS-HOST DISEASE: AN UPDATE ON INFECTIOUS
COMPLICATIONS
Wong, R.; Hicks, K.; Ippoliti, C.; Giralt, S.; De Lima, M.; Cohen, A.;
Khouri, I.; Champlin, R.; Couriel, D. MD Anderson Cancer Center,
Houston, TX
Objective: To evaluate the infection rate in patients treated with
infliximab for GVHD. Design: Retrospective descriptive study.
Methods: We evaluated 141 patients treated with infliximab for
acute (n=88) or chronic (n=53) GVHD following allogeneic
hematopoietic stem cell transplantation. All patients were on
steroids and most of them were on other immunosuppressive
agents. Patients were treated with 10 mg/kg of inﬂiximab weekly
for a median of 2 doses (range 1-12). Infections were documented
up to 6 months following the last dose of inﬂiximab. An infection
or infectious episode was deﬁned by clinical manifestations and/or
microbiological evidence of infection. Results: One hundred and
fifteen patients had a total of 345 infections, with a mean of 3
infectious episodes per patient (range 1-12). Most of these infec-
tions (n=309, 89.6%) had microbiological documentation and
occurred in patients with acute GVHD (68.4%). The median time
to infection was 66 days following the first dose of infliximab
(range 1-314 days). There were a total of 381 positive cultures for
345 infections. In 59 cases, infections were caused by multiple
organisms. Positive cultures included: 124 gram positive bacteria,
60 gram negative bacteria, 95 viruses, 93 fungi, 4 pneumocystis
carinii and 5 atypical mycobacteria. 58 patients developed a total
of 93 fungal infections. Of these, 34.4% were secondary to
Aspergillus or Fusarium species. Among viral infections, the most
common pathogen was CMV (55.8%). Eighty-eight patients
(62.4%) died during the study period, and approximately half of
these deaths (n=43) were secondary to infection. Conclusions:
Advanced GVHD and its treatment are associated with a high risk
of infectious complications. In patients treated with infliximab,
this risk remained high, with a substantial number of viral and
fungal infections. New immunosuppressive modalities should be
evaluated earlier in the course of GVHD and within the setting of
a clinical trial.
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GVH-PROPHYLAXIS WITH ANTITHYMOCYTE GLOBULINE (FRESE-
NIUS) IN RECIPIENTS OF MATCHED AND MISMATCHED UNRELATED
DONOR TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA: A
RETROSPECTIVE ANALYSIS
Zander, A.R.; Schleuning, M.; Kroeger, N.; Finke, J.; Zabelina, T.;
Berger, J.; Beelen, D.W.; Trenschel, R.; Schwerdtfeger, R.;
Baurmann, H. University Hospital Eppendorf, Hamburg, Germany
Matched unrelated donor transplant has an increased risk of
severe graft versus host disease and transplant related mortality
(TRM). ATG has been introduced to decrease GvHD and to facil-
itate engraftment. We conducted a retrospective analysis of Frese-
nius ATG, n = 145, average = 90 mg/kg bw, range 40 – 90 mg/kg
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bw compared with a no-ATG group, n = 188, age, sex, HLA-
matched versus mismatched were comparable. Cell source (bone
marrow vs. peripheral blood stem cell) was signiﬁcantly different
in the 2 groups. Results: See table below. Conclusion: ATG Frese-
nius decreases the incidence of acute GvHD and TRM and leads
to a signiﬁcant better overall survival. A prospective randomized
study is needed to evaluate the deﬁnite role of ATG in HSCT.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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HARVESTING AND TRANSPLANTATION OF ALLOGENEIC PERIPHERAL
BLOOD STEM CELLS (PBSC) FROM HEALTHY VOLUNTEER DONORS <
17 YEARS OF AGE
Calderwood, S.1; Sweetman, R.1; Falk, P.M.2; Smith, D.1; Wang, S.1;
Rosenthal, J.1 1. City of Hope National Medical Center, Duarte, CA;
2. Kaiser Permanente, Duarte, CA
Purpose: Evaluate safety and efﬁcacy of PBSC harvesting from
allo donors < 17 yo, and evalute engraftment and incidence of
acute and chronic GVHD in recipients. Methods: Retrospective
review of medical records of all allo PBSC donors < 17 yo and of
all recipients of PBSC transplants from these donors. Results.
Between 10/97 and 10/01, 29 PBSC harvests were performed on
donors < 17yo. Mean age of the donors was 9.95 y (range: 0.96 –
16.5y). Mean wt of the donors was 42.9 kg (range 10-113 kg).
Donors received G-CSF at a mean dose of 9.8 ug/kg (range 8.5 –
10.5 ug/kg) for a mean of 4.5 days (range 2-6 days). 13/29 donors
required temporary central venous catheters. A mean of 16.8 1
(range 2.5 – 52 1) of blood were processed in a mean of 1.46
leukaphereses/donor (range 1-3). A mean of 7.65 x 10e6 CD34+
cells/ kg recipient Bwt were collected (range 1.41 – 22.04). 27/29
donors yielded an adequate number of CD34+ cells, 2/29 required
supplemental BM harvesting. Donors < 20 kg had the extra-cor-
poreal circuit primed with PRBC, no other transfusions were
required. 29 transplants were performed. 28/29 pts engrafted, one
died at day 7 without engraftment. Mean time to ANC > 500 was
18.5 days (range 9-33 days). Acute GVHD > grade I occurred in
11/27 pts at risk (40%). Chronic GVHD developed in 9/22
patients at risk (41%). At a mean F/U of 7.2 months (range .25 –
24 months), 24/29 (83%) patients were alive and 20/29 (70%)
were free from treatment failure. Conclusions: PBSC harvesting
appears safe and efﬁcacious for allo donors < 17 yo, with engraft-
ment, acute and chronic GVHD rates similar to those reported
with BMT. PBSC harvesting should be further evaluated as an
alternative to BM harvesting for pediatric donors.
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CLASS I HLA ANTIGEN DISPARITY AND CLINICAL OUTCOME AFTER
UNRELATED DONOR (URD) BONE MARROW TRANSPLANTATION (BMT)
Ho, V.T.1,2; Cutler, C.S.1,2; Zahrieh, D.1; Neuberg, D.1; Liney, D.2;
Sese, D.1; Soiffer, R.J.1,2; Antin, J.H.1,2 1. Dana-Farber Cancer Insti-
tute, Boston, MA; 2. Brigham and Women’s Hospital, Boston, MA
Background: Some studies suggest HLA Class I disparity
adversely affects clinical outcome after URD BMT. However, the
importance of HLA Class I matching remains controversial.
Methods: We performed a retrospective analysis of 132 patients
who underwent BMT from unrelated donors at our institution
between 5/97 and 6/00. Eighty-one were fully matched at HLA-A,
B, C, DR. Fifty-one were mismatched at HLA-A±C (n =10),
HLA-B±C (n =20), or HLA-C alone (n=21), and were matched at
HLA-DR. All received Cytoxan/TBI conditioning with
methotrexate plus cyclosporine or tacrolimus as graft-versus-host
disease (GVHD) prophylaxis. Clinical outcomes investigated
included grade III-IV GVHD and survival. Results: The HLA
Class I mismatched and fully matched cohorts were similar in
donor and recipient age, gender disparity, and disease status at
transplant. Grade III-IV GVHD was observed in 1/10 (10%) of
patients mismatched at HLA-A±C, 5/20 (25%) patients mis-
matched at HLA-B±C, and 4/21(19%) patients mismatched at
HLA-C alone. None of these were statistically different compared
to the fully matched cohort, where the incidence of grade III-IV
GVHD was 12/81(15%) (p= 0.67). The actuarial 1-year survival
was 30%, 60%, and 62% for patients mismatched at HLA-A±C,
B±C, and C alone, respectively, and 51% in the fully matched
cohort (log rank p= 0.39, 3df). In multivariate Cox regression
analysis adjusted for donor/recipient age, gender disparity, disease
status, and CMV status at transplant, there remained no signiﬁ-
cant difference in survival among HLA-A±C, B±C, and C only
mismatched and the fully matched groups. Conclusion: In URD
BMT, donor-recipient disparity in HLA A±C, B±C, or C alone
does not inﬂuence grade III-IV GVHD or adversely affect survival
compared to fully matched pairs. HLA class I mismatches may
provide viable transplant options for patients who do not have
fully matched donors.
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COMPREHENSIVE BANKING AND TRANSPLANTATION OF SIBLING
DONOR CORD BLOOD
Reed, W.1; Smith, R.1; Dekovic, F.1; Lee, J.Y.3; Saba, J.D.1; Trachten-
berg, E.1; Walters, M.C.2; Lubin, B.H.1 1. Children’s Hospital Oakland
Research Institute, Oakland, CA; 2. Children’s Hospital Oakland, Oak-
land, CA; 3. Alta Bates Summit Medical Center, Berkeley, CA
Banking of cord blood (CB) for transplantation of unrelated
hematopoietic stem cell (HSC) recipients is established. However,
directed donor banking of CB for siblings affected by life-threat-
ening hematopoietic disorders has not been widely investigated
and procedures for sibling donation have not been standardized.
We devised such procedures and policies for all aspects of eligibil-
ity, enrollment, laboratory testing, CB collection, graft characteri-
zation, storage, and release from medical quarantine. Families
were eligible if they were caring for a child with a disorder treat-
able through HSC transplantation and expecting birth of a full
sibling. Six hundred twenty eligible families from 42 states have
been enrolled thus far. CB collections were performed at >300
hospitals. No family was deferred based on health history or infec-
tious disease testing, but departures were documented so they
could be considered as individual risk factors if that CBU was
requested for release from quarantine. Disease categories of sib-
ling recipients included: malignancy, sickle cell anemia (SCA),
thalassemia major, non-malignant hematologic conditions, genetic
immune deﬁciencies, and metabolic errors. Mean CB volume and
nucleated cell count were 100.6 ml (range: 20 -240) and 8.9x108
(range: 1-18 x 107 ), respectively, for all collected CBUs. Cellular
characteristics were judged adequate to transplant the sibling for
>85% of banked units. Fourteen CBUs have been released and
transplanted by 12 centers; 2 were combined with marrow from
the same sibling. Thirteen of the 14 CB units have engrafted suc-
cessfully. We conclude that national comprehensive banking of
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sibling donor CB can be accomplished with a high success rate
and in an environment guided by cGMP principles and that the
units banked will be utilized for transplant. The successful trans-
plantation of CBUs banked by this national program supports the
initiation of a prospective clinical trial of sibling CB transplanta-
tion for children with sickle cell anemia and thalassemia.
IMMUNE RECONSTITUTION
112
RECOVERY OF CYTOKINE SYNTHESIS IN PEDIATRIC RECIPIENTS OF
MATCHED SIBLING MARROW DONORS (MSD) UNRELATED MARROW
DONORS (URD)AND UNRELATED CORD BLOOD DONORS UCB)
Filipovich, A.H.1; Villanueva, J.1; Lee, S.1; Grimley, M.2 1. Children’s
Hospital Medical Center, Cincinnati, OH; 2. Lackland AFB, San Anto-
nio, TX
Late infections remain the major cause of death following URD
BMT and UCBT. No direct comparisons of immunoreconstitu-
tion after UCBT, URD, and MSD BMT have been reported .
Serial blood samples from 92 pediatric BMT pts. were assayed for
in vitro production of regulatory cytokines synthesized by activat-
ed antigen presenting cells (APC) : IL-12, TNFα,γIFN, IL-10 or
T cells :IL-2,IL-4, IL-10,γIFN, GM-CSF, as quantitated by
ELISA of culture supernatants. Conditioning protocols and Graft
vs. Host disease (GvHD) prophylaxis with CsA were similar for all
groups. Twenty three pts. had MSD, 45 – URD and 14 – UCB.
No signiﬁcant differences were found among the three groups in
mean age at BMT, nor proportions with non-malignant disease or
acute GvHD. Results indicate that production of APC derived
cytokines is highly dysregulated during the first post transplant
year; profoundly depressed synthesis of type 1 cytokines IL-12
and γIFN, and increased production of IL-10 and TNFα was
observed for all pts. compared to normal controls. Statistically
decreased levels of IL-12 were observed after URD BMT and
UCBT, while IL-12 synthesis recovered to normal range by 6
mos. after MSD BMT. Furthermore, IL-12 and γIFN production
was significantly lower in pts. with GvHD, while synthesis of
TNFα and IL-10 was not inﬂuenced by GvHD. With the excep-
tion of GMCSF production (which normalized in all pts. by 60
days) secretion of both type 1 (IL-2, γIFN) and type 2 (IL-4, IL-
10) T cell cytokines remained subnormal for at least one year in
all groups. These findings of depressed cytokine production by
both the innate and adaptive arms of the immune system may rep-
resent a key mechanism for the prolonged immunodeficiency
observed after mismatched BMT, although it’s cause(s) and cures
remain to be elucidated.
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A NOVEL METHOD FOR ASSESSMENT OF HEMATOPOIETIC
CHIMERISM AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
USING SINGLE NUCLEOTIDE POLYMORPHISMS
Hochberg, E.P.; Miklos, D.; Neuberg, D.; Mclaughlin, S.P.; Mattes-
Ritz, A.; Alyea, E.P.; Antin, J.; Soiffer, R.; Ritz, J. Dana Farber Can-
cer Institute, Boston, MA
Attainment of either stable mixed chimerism or full donor
hematopoiesis is a critical endpoint of hematopoietic stem cell
transplantation (HSCT). Current methods for assessment of
chimerism based on STR, VNTR or microsatellite polymor-
phisms are time-consuming, expensive and difficult to quantify.
The vast majority of human genetic disparity is generated by sin-
gle nucleotide polymorphisms (SNP) and therefore direct meas-
urement of SNP should provide a more robust tool for the detec-
tion and quantitation of chimerism. Pyrosequencing™ is a rapid
short-read quantitative sequencing technology based on the detec-
tion of pyrophosphate release by DNA polymerase when a
nucleotide complementary to the evaluated strand is added. We
established a panel of 14 SNP with allele frequencies near 50%
and optimized conditions for PCR from genomic DNA and sub-
sequent Pyrosequencing. In a test panel of 90 normal individuals,
each SNP reliably distinguished between homozygote and het-
erozygote genotype. Measured allele frequencies for this panel
ranged from 26-50%. Using this SNP panel at least 2 informative
loci were identiﬁed in paired samples of genomic DNA from 25
patients and their HLA-identical donors. The median number of
informative loci was significantly higher (p=0.01) in 12 patients
with unrelated donors (9 SNP) compared to 13 patients with
HLA-identical sibling donors (5 SNP). A smaller panel of 7 SNP
can provide at least a single informative locus in 99% of HLA-
identical pairs. Pyrosequencing of known mixtures of genomic
DNA from HLA-identical individuals demonstrated that the
quantitative assessment of chimerism is accurate and highly repro-
ducible. Analysis of serial samples following transplant demon-
strated that SNP sequencing provides a method for accurate and
quantitative assessment of hematopoietic chimerism in mixed cel-
lular populations as well as purified subpopulations. SNP-based
analysis of hematopoietic chimerism is an rapid, reliable and inex-
pensive technique that will assist in the analysis of outcomes fol-
lowing allogeneic HSCT.
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SLOW LYMPHOCYTE RECOVERY PREDICTS INCREASED RISK FOR
RELAPSE AFTER ALLOGENEIC BONE BARROW TRANSPLANTATION
FOR ACUTE LYMPHOCYTIC LEUKEMIA
Kumar, S.; Lacy, M.Q.; Inwards, D.J.; Tefferi, A.; Gastineau, D.A.;
Gertz, M.A.; Litzow, M.R. Mayo Clinic, Rochester, MN
Background: Allogeneic BMT is potentially curative in patients
with relapsed ALL and in those with poor prognostic factors.
However, relapse is an important cause of transplant failure. Lym-
phocyte recovery at four weeks post-transplant has been shown to
predict relapse in patients undergoing BMT for AML. Aim: To
evaluate if the rate of lymphocyte recovery after allogeneic BMT
predicts the risk of relapse in patients with ALL. Methods and
materials: Retrospective review of patients with ALL who under-
went matched related allogeneic BMT at our institution was done.
Forty-four transplants done over an 18-year period were exam-
ined. Only patients surviving 21 or more days post-transplant
were included for analysis. The absolute lymphocyte count (ALC)
at day-21 and day-30 post-transplant was obtained from the
records. The effect of ALC at each of these time points on the risk
of relapse was evaluated for different levels of ALC. Results: Six-
teen relapses occurred among the 44 eligible patients. Maximum
separation of two groups was seen at an ALC cutoff of 175/micro-
liter on day-21. Patients who had an ALC of less than 175/micro-
liter on day-21 were 4 times (95%CI; 1.4, 10.8) more likely to
relapse compared to those with ALC>175/microliter . Patients
with slower lymphocyte recovery had signiﬁcantly lower relapse-
free survival compared to the rest of the group (P=0.0038,log-rank
test). There was also a trend towards poorer overall survival
among those with a slow lymphocyte recovery (P=0.052; Log-rank
test). No such relation was seen at day 30 for any level of ALC.
Conclusion: Day-21 ALC post-allogeneic BMT for ALL is an
independent prognostic factor for risk of relapse. We propose that
information regarding lymphocyte recovery should be integrated
with other predictors of relapse and used to identify patients at
high risk for relapse after allogeneic BMT for ALL. These results
should be validated using independent databases.
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LYMPHOCYTES TRANSDUCED WITH EBV-ANTIGEN SPECIFIC T CELL
RECEPTORS DISPLAY HETEROGENEOUS LYTIC KINETICS
Orentas, R.J. Medical College of Wiscosnin, Milwaukee, WI
Bone marrow transplantation provides a unique window for
immune reconstitution of antigen-specific immune responses.
This includes reconstitution of protective immune responses to
Epstein-Barr virus (EBV) for the EBV-associated malignancies.
EBV-associated Hodgkin’s disease (EBV-HD) does not express
the immunodominant EBV latency antigens of the EBNA3 fami-
ly. The strong immune response to these antigens lay behind the
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success of adoptive immunotherapy for post-transplant lym-
phoma. EBV-HD does express the EBV-encoded latency mem-
brane protein (LMP)-2, which is recognized by the cellular
immune response in approximately half of healthy seropositive
volunteers (Lee, S.P. et al., 2000). However, in addition to not
being universally recognized, the overall magnitude of the CTL
response to LMP2 is weak. Our goal is to develop an
immunotherapeutic strategy to treat patients suffering from EBV-
associated HD. Toward that end, CTL clones specific for an
HLA-A2 restricted peptide from LMP2 were generated, the
TCR-alpha and -beta chains molecularly cloned, and then trans-
ferred to a retroviral expression vector. Packaged retroviral parti-
cles were then used to transduce activated PBMC. A fully func-
tional TCR was transferred to PBMC as demonstrated by both
cytolytic activity and gamma-IFN secretion. The retroviral
expression of a recombinant TCR allows the functional activity of
that TCR to be analyzed in different cellular settings, thus
demonstrating whether it is the physiology of the transduced lym-
phocyte or the sequence of the TCR that determines lytic activity.
To examine this in detail, activated PBMC were transduced with a
TCR vector, cloned by limiting dilution, evaluated for V beta
chain expression, and then re-assayed for cytolytic activity. Quan-
titative analysis of cellular lytic kinetics demonstrated that a wide
range of lytic activity was seen. It is therefore likely that the opti-
mal therapeutic benefit with transduced lymphocytes will be
gained by ﬁrst selecting those lymphocyte subsets which best sup-
port functional expression of transduced TCR.
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REGULATION OF LYMPHOPOIESIS IN THE STEADY-STATE THYMUS
Petrie, H.T. Memorial Sloan-Kettering, New York, NY
Continuous T lymphocyte production throughout life is
required for the maintenance of peripheral homoestasis. Under
normal circumstances, this process is carried out by the thymus. A
unique feature of differentiation in the post-natal thymus is that
lymphopoietic progenitors do not reside in situ, but rather derive
from bone marrow and continuously migrate to the thymus via
the bloodstream. Interruption of any step in this process leads to
abrogation of thymic lymphopoiesis. In spite of the critical nature
of these events, the signals that induce multipotent precursors to
home to the thymus, extravasate, and enter the thymic parenchy-
ma remain almost completely obscure. Further, the events that
trigger T lineage commitment and proliferative expansion of mar-
row-derived precursors within the thymus are also poorly under-
stood. To understand these processes, we have begun to assess sig-
naling requirements and signaling environments in region ally
deﬁned compartments of the thymus, including vascular / perivas-
cular tisues at the sites of precursor entry, as well as from stratiﬁed
regions of the thymic cortex where differentiation and prolifera-
tion take place. By analyzing receptors on lymphoid progenitors
and their ligands on stratified stromal elements, we are piecing
together the signals that induce blood-borne progenitors to
replenish the steady-state thymus, as well as to proliferate, differ-
entiate into T lymphocytes, and maintain peripheral homeostasis.
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A POTENTIAL REQUIREMENT FOR C-KIT DURING PRECURSOR
MIGRATION IN THE STEADY-STATE MURINE THYMUS
Prockop, S.; Palencia, S.; Petrie, H. MSKCC, New York, NY
The thymus performs several essential functions during the
steady-state production of post-natal T lymphocytes, including
precursor proliferation, T lineage commitment, and positive and
negative selection. Other than those functions that are attributable
to the TCR specificity, most of the factors that mediate these
processes remain undeﬁned. We have recently shown that speciﬁc
stages of precursor development are localized to discrete sub-
regions of the murine thymic cortex, suggesting that one major
inﬂuence on this development may involve the movement of pre-
cursor cells between distinct signaling compartments. To study
this, we are generating stable hematopoietic/thymic chimeras,
using bone marrow from mice expressing defects in cell adhesion
or migration transplanted into normal, congenically-marked
recipients. One such case is exempliﬁed by c-kit, which was origi-
nally found by virtue of a defect in melanocyte migration (gene
symbol W, for white-spotting). This defect results from an inabili-
ty of c-kit mutant cells to activate beta-1 integrin, which is nor-
mally a consequence of kit ligand binding. Virtually all thymocyte
precursors from normal mice express beta-1 integrin, as well as c-
kit. Further, thymuses from c-kit mutant mice are markedly
hypocellular, although steady-state lymphopoiesis has not been
well characterized due to peri-natal lethality. Using the chimeric
system described above, we ﬁnd that c-kit mutant precursors fail
to localize symmetrically in the steady state thymus, but instead
are found clustered in a dense region near the medial border of
each lobe. This defect in cell migration correlates with other
developmental defects, including the near absence of CD25+ pre-
cursors and decreased cell proliferation. Together, our data reveal
a previously undeﬁned requirement for c-kit in the localization of
precursor thymocytes in the post-natal thymus and, in turn,
underscore the importance of migration between discrete cortical
microenvironments for normal thymocyte differentiation and
homeostasis.
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DEMONSTRATION OF T CELL-MEDIATED RESISTANCE TO BONE
MARROW ENGRAFTMENT IN MINOR HISTOCOMPATIBILITY DIS-
PARATE MICE WITHIN 48 HOURS POST-BMT
Shatry, A.M.; Mammolenti, M.; Jones, M.; Levy, R.B. University of
Miami Medical School, Miami, FL
Failure of BM engraftment can result from host resistance medi-
ated by NK cells or donor-specific T cells. However, the early
kinetics leading to rejection of progenitor cell allografts are not
well understood. We are examining early events in resistance by
determining CFU IL-3 activity in the spleen and marrow at 12, 24,
48 and 72 hours post-BM transplantation (BMT) involving minor
histocompatibility antigen (MiHA) mismatched mice (BALB.B →
B6). Similar to aplastic anemia patients who are often sensitized to
donor antigens, recipient mice were primed with 3 x 107 donor
cells 4/5 weeks prior to transplant and lethally irradiated (9 cGy)
on Day -1. Twelve hours after transplant, CFU levels in primed
B6 recipient spleens(160 ± 92) were similar to numbers present in
unprimed recipients (109 ± 16). However, by 24 hours, splenic
CFU numbers although still detectable in primed recipients, were
lower than in unprimed recipients. By 48 hours, CFU-IL3 were
clearly lower in recipients primed to donor MiHA. Primed B6
recipient spleens of BALB.B progenitors had upto 30-fold lower
CFU than primed recipients of syngeneic B6 progenitors 48-72
hours post-BMT. In an independent BALB.B → B6 experiment,
kinetics were examined in the spleen and marrow of I.V. BMT
recipients. The pattern of rejection in the BM paralleled that
observed in the spleen. To compare kinetics of T cell resistance to
NK cell-mediated resistance, BM cells were transplanted in
MHC-disparate mice (BALB/c → B6). NK cell-mediated resist-
ance was already evident in recipient mice by 24 hours post-BMT.
Together, the results indicate that primed T cells can effect BM
graft resistance against MiHA with similar kinetics as NK-cell
mediated resistance across MHC differences. Initial studies intro-
ducing BM cells directly into the host marrow cavity revealed
higher progenitor frequencies in this compartment compared to
the spleen, raising issues regarding compartmental resistance.
LATE EFFECTS/QUALITY OF LIFE
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SEVERE MYXOEDMA CAUSED BY ATROPHIC THYROIDITIS THAT
PROGRESSED RAPIDLY TWO YEARS AFTER ALLOGENEIC BMT
Aoki, Y.2; Nonoyama, S.1 1. Tokyo Medical and Dental University,
Bunkyo-ku, Japan; 2. Bokutou Tokyo Metropolitan Hospital, Koutou-
ku, Japan
A three-year old boy rapidly developed severe myxoedema two
years after an allogeneic bone marrow transplantation (BMT). His
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conscious level was impaired and he had sleep apnea, with the
decrease of SpO2 to 76%. Chest X-P revealed the presence of
bilateral pleural effusion. Blood tests showed elevated creatinine
kinase (CK) and total cholesterol levels in his serum. From such
observations hypothyroidism was suspected, endcrinological
examination substantiated this preliminary diagnosis with a thy-
roid stimulating hormone (TSH) level of: 199, fT3: <0.1, fT4:
<1.0. The patient had no struma and an ultrasonography indicated
an extremely atrophic thyroid organ, there was almost no uptake
of 131I to the thyroid by scintiscanning. Interestingly, a large quan-
tity of thyroid-stimulation blocking antibody (TSBAb) (99.5%,
normal: <30%) was continuously detected in his serum. TSBAb is
known to block the binding of TSH to the thyroid, and to cause
atrophic thyroiditis. From these data, it was diagnosed that the
patient suffered atrophic thyroiditis resulting in severe myxoedma.
Following oral administration of thyroid hormone (levothyroxine),
his myxoedema was cured and the patient is now well and active,
although his serum TSBAb level remains high. The TSBAb from
his donor, a 43 year old female is now being examined. We con-
clude that atrophic thyroiditis, caused by TSBAb must be consid-
ered as a severe late effect of BMT.
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UTILIZATION OF THE INTERACTIVE VOICE RESPONSE (IVR) SYSTEM TO
RECORD SYMPTOMS FOLLOWING AUTOLOGOUS TRANSPLANTATIONS
Beattie-Palmer, L.N.; Anderson, K.O.; Brown, J.O.; Mobley, G.;
Giralt, S.; Neumann, J.L.; Mendoza, T.; Wang, S.; Cleeland, C.S.
University of Texas M.D. Anderson Cancer Center, Houston, TX
Autologous transplantation patients typically experience multi-
ple symptoms during and beyond the transplant period. Accurate
symptom assessment can be difﬁcult. IVR system technology can
be used to facilitate accurate symptom assessments, through com-
bining the use of a telephone with computer technology. In our
study the IVR system called patients at scheduled times to admin-
ister the M.D. Anderson Symptom Inventory (MDASI). The
MDASI asks patients to rate 14 symptoms on a scale of 0 to 10.
The participants were 39 autologous patients (26 multiple myelo-
ma, 10 non-Hodgkin’s lymphoma, 3 breast cancer) who reported
their symptoms during days 4-29 post-transplant (T5) and months
2-6 post-transplant (T7). Fifty-nine percent were male. The mean
age was 52 years. Eighty-seven percent were white non-Hispanic.
During T5, the percentage of symptom assessments that were
rated as ≥5 included: fatigue (40.4%), lack of appetite (36.5%),
feeling weak (35.3%), disturbed sleep (30.6%), feeling sick
(21.2%), and diarrhea (20.4%). By month 6 post-transplantation
(T7), the percentage of symptom assessments that were still rated
as ≥ 5 included: fatigue (15.6%), distress (15.6%), pain (12.5%),
and disturbed sleep (12.5%). During T5 and T7, 77% and 76.9%
of the IVR calls were completed successfully. When asked to rate
the IVR on a scale of 0 to 10, patients reported feeling comfort-
able using the IVR (mean = 8.1), it was easy to use (mean = 8.8),
and it should be part of regular care (mean = 7.7). Of the 39 par-
ticipants, 31 used the IVR for 6 months. Our results indicate that
the IVR system is a convenient and efficient way of assessing
patient symptoms and could be utilized as a part of regular clinical
follow-up.
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COGNITIVE OUTCOME AFTER PEDIATRIC BONE MARROW TRANSPLANT
Harris, L.L.; Khan, S.P. Baylor College of Medicine, Houston, TX
Effect of bone marrow transplantation (BMT) and its associated
treatments (e.g., chemotherapy, irradiation) on cognitive and
socio-behavioral functioning has been noted. The research on this
topic is based largely on clinical observation, showing variability
between studies in the patterns of delay and deﬁcit. There is a par-
ticular lack of research investigating the effects of BMT on
school-aged and pre-adolescent children. We retrospectively
reviewed 10 children who had received both a pre-BMT and post-
BMT neuropsychological evaluation (median length of time
between assessments was 1.2 years). Reason for BMT was malig-
nancy (leukemia/lymphoma; ALL=5, AML=2, NHL=1) or prema-
lignant disorder (myelodysplastic syndrome=1) or metabolic disor-
der (Hurler syndrome=1). Domains assessed included general cog-
nitive ability (encompassing intelligence, memory, language), ﬁne
motor skills and adaptive functions. In all three domains the child
with lymphoma and the child with pre-leukemia showed improve-
ment while the two children with AML both showed consistency
of performance. The child with Hurler syndrome showed decline
in motor functioning but normative progression in general mental
ability. The 5 children with ALL showed variable outcome. With-
in the domain of general mental ability, individual children
showed improvement in some areas and decline in other areas.
However, motor functioning mirrored the effect of general cogni-
tive functioning within child. Regarding adaptive functions, all
children showed improvement with the exception of the child with
Hurler syndrome. Data will be presented in case study format. In
summary based on their pre-BMT etiology, variability was seen in
post-BMT change in functioning. Recognizing this variability, our
center has implemented an empirically-based standardized test
battery that is administered within two months pre-BMT and
again one-year post-BMT. Data from these assessments will allow
for systematic investigation into the cognitive outcome of pedi-
atric BMT stratified by pre-BMT etiology as well as highlight
speciﬁc areas in need of intervention for individual children.
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QUALITY OF LIFE MONITORING IN PATIENTS WITH MULTIPLE SCLERO-
SIS AFTER AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION
Novik, A.A.; Ionova, T.I.; Bisaga, G.M.; Melnichenko, V.Y.; Chelom-
bit, L.V.; Denisov, P.I. Russian Cooperative Group of High Dose
Chemotherapy in Autoimmune Diseases, Saint-Petersburg, Russian
Federation
As quality of life (QoL) is one of the important outcomes of MS
treatment, QoL monitoring of MS patients after autologous
peripheral stem cell transplantation (APSCT) is worthwhile. The
aim of the study was to monitor QoL of four patients with MS
before and at different time-points after APSCT (EBMT proto-
cols). Materials and methods: QoL evaluation (FACT-BMT -
BMT speciﬁc, FAMS - speciﬁc for MS patients) was provided at
baseline, at discharge and at 3, 6, 8,12, 18, 24 and 30 months after
APSCT. Results: Stabilization of the disease was achieved in all
cases. Follow-up period varied from 8 to 30 months. In three
patients QoL improvement on the majority of scales was achieved
within 3 months after APSCT as compared with baseline with a
distinct tendency to further improvement at late follow-up. For the
patient P.(female; 48 years old; spinal primary progredient sub-
type; EDSS 7,5), who had initially very low QoL parameters, 2-3
folds increases in QoL parameters by FAMS scales were revealed 3
months after APSCT. For the patient F.(female; 38 years old; cere-
bral-spinal secondary progredient subtype; EDSS - 5,0) at dis-
charge the decrease in physical, social, and functional well-being as
well as general QoL was observed. In 3 months after APSCT the
above QoL domains became better. A year after APSCT QoL
parameters improved significantly and they remained stable
throughout the follow-up period. The most remarkable improve-
ment in the majority of QoL domains was observed a year after
APSCT for the patients with more than a year follow-up. Conclu-
sion: APSCT in patients with MS results in improvement of their
QoL. QoL parameters impaired by MS improve 3 months after
APSCT with a tendency to further improvement of patient’s well-
being within a year after APSCT. The most remarkable QoL
improvement takes place a year after APSCT.
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THE OVERALL CLINICAL SAFETY OF VORICONAZOLE (V)
Tomaszewski, K.1; Nurbhai, S.2; Baruch, A.3 1. Pﬁzer Global Research
& Development, Sandwich, United Kingdom; 2. Pfizer Global
Research & Development, New London; 3. Pfizer Pharmaceuticals
Group, New York
Background: V, a novel broad-spectrum antifungal agent, is
available as both intravenous (i.v.) and oral formulations. Those
receiving V often need extended treatment, are severely ill with
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low neutrophil counts, and receive numerous concomitant med-
ications. Methods: V safety was assessed in a clinical program of
>1000 subjects. The principal comparative agent was ampho-
tericin B formulations (AmB; N=571). The most frequently
observed adverse events (AEs) and discontinuations (D/Cs) were
assessed. Results: AEs associated with V are abnormal vision
(described elsewhere), elevated liver function (LFT) tests and rash
(see Table- values are % of subjects reporting AEs). Other fre-
quent AEs are acute renal failure, sepsis, hallucinations, fever,
vomiting and diarrhea. Except for abnormal vision and hallucina-
tions, AEs were reported at a similar, or greater, rate with AmB.
The D/C rate due to AEs with V was low (~2/patient yr), with the
majority (36%) for elevated LFTs. There was a long duration of
treatment (mean 42 days; range 1-882d) testifying to V’s accept-
able tolerability. Conclusions: AEs involving possible hepatic
effects are manageable by patient monitoring and dose adjustment
as needed. Other AEs are either expected to occur infrequently or,
for abnormal vision or rash, rarely affect treatment. Oral and i.v.
dosing of V allows patient-care flexibility and possible extended
treatment. Overall, an acceptable safety profile for V has been
established in clinical trials.
LEUKEMIA
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RANDOMIZED TRIAL OF BUSULFAN (BU) VS. TOTAL BODY IRRADIA-
TION CONDITIONING REGIMENS FOR CHILDREN WITH ALL: A PEDI-
ATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM STUDY
Bunin, N.; Aplenc, R.; Wall, D.; Kamani, N.; Shaw, K. Children’s
Hospital of Philadelphia, Philadelphia, PA
Conditioning regimens for children with ALL have generally
included TBI, which may result in significant sequelae. A few
small series have utilized busulfan (Bu)for patients (pts) with
ALL, but Bu vs. TBI containing regimens have not been stud-
ied in ALL in a prospective randomized trial. This study
opened in 1997 for pts <21 years with ALL in high risk CR1, as
well as CR2 and CR3. Stem cell source was not specified. Con-
ditioning included either Bu (16-20 mg/kg) or TBI 1200 cGy/6
fractions) and etopophos 40 mg/kg and cyclophosphamide 120
mg/kg. GVHD prophylaxis was CSA +/-methotrexate. Ran-
domization was stratified based upon duration of CR,CR status
and prior CNS irradiation. 43 patients were enrolled; 21
received Bu and 22 TBI. Median pt age was 8 yrs (0.5-20), and
M:F was 29:14. Remission status included: CR1: 12, CR2: 25,
CR3: 6. Stem cell sources included related donor marrow
(MRD) for 21, and unrelated marrow/cord (URD) for 19/3. At
a median follow up of 22 mos, OS is 57% at 2 years, with 46%
for Bu and 66% for TBI pts (p=0.08). EFS is 47%, with 32%
for Bu and 55% for TBI pts (p=0.04 ). When analyzed by stem
cell source, EFS is 55% for MRD, with no significant difference
between Bu and TBI. However, for URD, EFS is 20% for Bu
and 57% for TBI (p=0.04). Bu was inferior for pts <6 yrs (17%
vs 73%,p=0.03), but there was no difference between Bu and
TBI in pts >6 yrs.Relapses (14) were similar in both arms, and
occurred 3-24 mos post transplant. Non relapse mortality was
Bu:5,and TBI:2. The study was closed early due to poor accrual.
Although these data are hampered by small numbers, this
prospective study suggests that Bu is inferior to TBI for pedi-
atric pts with ALL SCT.
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DIFFERENTIAL ACTIVATION OF ANTI-TUMOR T-CELLS IN VIVO BY
B7-2+ VS. B7-1+ MURINE LEUKEMIA CELLS
LaBelle, J.L.1; Jeppsen, P.1; Gerber, K.A.1; Blazar, B.R.2; Truitt, R.L.1
1. Medical College of Wisconsin, Milwaukee, WI; 2. University of Min-
nesota, Minneapolis, MN
The introduction of genes for B7 costimulatory molecules into
B7-negative tumor cells can induce anti-tumor T-cell reactivity to
some tumors, but B7-1 and B7-2 do not always have equivalent
effects on the longevity and speciﬁcity of the antitumor response.
We previously reported that mice injected subcutaneously with a
lethal dose of C1498 (a murine NKT-cell/myeloid leukemia)
expressing B7-2 (C1498/B7-2) resulted in transient growth fol-
lowed by CD8-T-cell-mediated tumor regression and permanent
immunity to parental tumor. In contrast, B7-1+ C1498
(C1498/B7-1) grew progressively, leading to death of the host.
The inability of C1498/B7-1 to generate an anti-tumor response
in vivo was not due to a lack of immunogenicity since both B7-1+
and B7-2+ C1498 activated tumor-specific CTL in vitro in the
presence of exogenous cytokines. Analysis of responding T-cells
from these cultures by TCR spectratyping suggested that B7-1
and B7-2 activated distinct tumor-speciﬁc T-cell subpopulations
as evidenced by differential expansion of TCR Vß families. We
hypothesized that differential activation of responding T-cells
might have contributed to the opposite responses to C1498/B7-1
(progressor) and C1498/B7-2 (regressor) in vivo. To determine
whether differences in the responding TCR Vß utilization
occurred, tumor-infiltrating-lymphocytes (TILs) were isolated
from excised tumors on individual mice and compared by spec-
tratyping. Single mice were injected at three different sites with
C1498, C1498/B7-1, and C1498/B7-2 to control for differences in
individual responses. Preliminary data shows (a) that B7+ C1498
resulted in a broader TCR-family utilization than the parental
C1498 and (b) that C1498/B7-1 and C1498/B7-2 resulted in the
differential activation of responding T-cell populations in vivo.
Thus, B7-1 and B7-2 appear to initiate an immune response
through distinct subpopulations of T-cells.
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CHANGES OF REACTIVE OXYGEN SPECIES, TELOMERASE, RELATED
GENES AND CA2+ IN APOPTOSIS OF LEUKEMIA CELLS INDUCED BY
AS2O3 AND SEO2
Wei, Y. Lanzhou Hematology, Lanzhou, China
Arsenic trioxide (As2O3) and selenium dioxide (SeO2) on prolif-
eration, apoptosis, telomerase activity, reactive oxygen species
(ROS) and Ca2+ levels in three leukemia cell lines NB4, K562 and
HL-60 were investigated. The results showed that As2O3 0.6
mmol/L induced 44.9 % apoptosis in NB4 cells only, however,
when concentrations were increased to 2.7 and 8.1 mmol/L respec-
tively, 58.3 % and 62.3 % apoptosis signiﬁcantly exhibited in K562
and HL-60 cells. Down regulated telomerase activity, Bcl-2
expression, and up-regulated P53 protein expression were
observed. NAC 4 mmol/L, CAT 80 UmL, natrii dimercaptosussi-
nas (NDMS) 200 mmol/L, and Quin 2 20 mmol/L could down-
regulate apoptosis as well as P53 expression variously induced by
As2O3. NAC or CAT alone not only declined telomerase activity
respectively in three cell lines, but also significatly with As2O3
exacerbated telomerase activity, whereas Quin 2 inhibited telom-
erase decline. NDMS showed no effect on telemerase. Four chemi-
cals showed different regulation effects on the decline of Bcl-2
expression, ROS and Ca2+ levels in three tested cell lines. SeO2 at
10 and 30 mmol/L inhibited proliferation of three leukemia cell
lines. 30 mmol/L SeO2 treated for 48 h induced 54.0 %, 46.5 %,
49.6 % apoptosis in NB4, K562, and HL-60 cells respectively, and
down-regulated Bcl-2 expression in NB4 and K562 but not in HL-
60 cells, it also markedly decreased telomerase activities as well as
declined ROS and Ca2+ levels among three cell lines. Above four
chenicals showed either stimulating or inhibiting effects on apop-
tosis, ROS, and Ca2+ levels during treatment with SeO2. The
declines telomerase activity, ROS and intracellular Ca2+ levels as
well as down-regulation of Bcl-2 and up-regulation of P53
involved in apoptosis induced by As2O3 and SeO2.
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IMMUNOGENETHERAPY OF LEUKAEMIA THROUGH TCR TRANSFER
Xue, S.1; Voss, H.2; Gao, L.1; Bendle, G.1; Theobald, M.2;
Stauss, H.1 1. Imperial College of Science, Technology and Medi-
cine, London, United Kingdom; 2. University of Mainz, Mainz,
Germany
We have previously described the allo-restricted CTL approach
to circumvent immunological tolerance to self-proteins expressed
at elevated levels in tumour cells. In vitro studies have shown that
human and murine allo-restricted CTL can selectively kill tumour
cells, whilst expression levels of the target antigen in normal cells
are insufficient to trigger CTL killing. A major limitation of
immunotherapy in the human setting is that infusion into MHC
mismatched patients would stimulate an immune response against
alloantigens expressed by the infused CTL. We are using the
murine system to explore a strategy that takes advantage of the
unique tumour-speciﬁcity of allo-restricted CTL, and avoids the
complication of recipient immune responses against alloantigens.
The T cell receptor (TCR) of murine allo-restricted CTL speciﬁc
for mdm2, a nuclear protein often overexpressed in tumors, were
cloned into retroviral vectors with the aim to transfer the TCR
into normal CD8 T cells. We will show data indicating expression
of the transferred TCR, and present the functional analyses of
transduced CD8 T cells.
PEDIATRIC DISORDERS
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UNRELATED DONOR STEM CELL TRANSPLANTATION FOR LIFE-
THREATENING HEMOPHAGOCYTIC DISORDERS: PRELIMINARY
RESULTS FROM THE NATIONAL MARROW DONOR PROGRAM
PILOT STUDY
Baker, K.1; Gross, T.G.2; DeLaat, C.A.2; Matlack, M.3; Nelson, G.O.3;
Filipovich, A.H.2 1. University of Minnesota, Minneapolis, MN;
2. Children’s Hospital Medical Center, Cincinnati, OH; 3. National
Marrow Donor Program, Minneapolis, MN
Allogeneic stem cell transplant (SCT) is the only curative treat-
ment for patients with life threatening hemophagocytic disorders,
but <10% have matched sibling donors available. This study was
designed to evaluate the efﬁcacy of unrelated donor (URD) SCT
for patients with hemophagocytic lymphohistiocytosis (HLH,
familial or sporadic), X-linked lymphoproliferative disease (XLP),
and Chediak-Higashi syndrome (CHS) who had donors ascer-
tained through the National Marrow Donor Program (NMDP).
The preparative regimen consisted of busulfan (4mg/kg d-9 to d-
6), cyclophosphamide (50mg/kg d-5 to d-2), etoposide (300mg/m2
d-5 to d-3) and anti-thymocyte globulin 30mg/kg d-2, -1 and d+1,
+2). Since 1997 31 patients have been enrolled (HLH (23), XLP
(4), and CHS (4). Follow-up data is currently only available on 16
patients, all with HLH. 63% were males. Median age at diagnosis
was 1.2 yr (range .1-14.7yr) and median age at time of SCT was
2.0yr (range .4-18yr). Time from diagnosis to SCT was a median
of 0.4yr (range .3-3.2yr). 62% were HLA 6/6 matched and 38%
were HLA 5/6 matched. All patients surviving >28days (15/16)
engrafted at a median of 16 days (range 11-31days). Median fol-
low-up is 0.8yr (range .1-4yr) and the projected overall survival at
4yrs is 51% (95% conﬁdence interval (CI) 24%-78%). Causes of
death included infection (3), GVHD (1), graft rejection/failure (1),
toxic (1), recurrent HLH (1). The cumulative incidence of grade
III-IV acute GVHD was 44% (95% CI 20%-68%), and of chron-
ic GVHD was 9% (95% CI 0-26%). Survival of patients treated
“on study” as compared to all other HLH transplants in the
NMDP registry was 51% vs. 36%, although this difference was
not statistically significant (p=0.40). Problems remain with
aGVHD and transplant related mortality. When completed, this
multi-center trial facilitated by the NMDP, will further deﬁne risk
factors important for successful transplant outcome in this difﬁcult
group of disorders.
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IMPROVED OUTCOMES WITH A FLUDARABINE-BASED TRANSPLANT
PREPARATIVE THERAPY FOR ALTERNATIVE DONOR TRANSPLANT IN
CHILDREN WITH FANCONI ANEMIA: RESULTS OF THE FIRST 10
PATIENTS
Harris, R.E.; Boyer, M.; Gross, T.; Loechelt, B.; Filipovich, A.; Thom-
son, B.; Sande, J.; Smith, F. Children’s Hospital Medical Center,
Cincinnati, OH
Alternative donor transplant for patients with Fanconi anemia
(FA) is associated with poor engraftment (20-35% graft rejection-
GR rate), and often severe GVHD, organ toxicity and infection,
with survival of only 20-40%. Intensification of the preparative
regimen has not reduced the rate of GR or improved survival. T-
cell depletion (TCD) has reduced GVHD, but increased GR. Ten
FA patients with alternative donors at our center have received a
low-dose regimen of cytoxan 20mg/kg, TBI 450cGy and ATG to
which we have added ﬂudarabine 120mg/m2. 5 patients received
G-mobilized TCD PBSC (Isolex, <100,000 CD3/kg); 5 received
partially-TCD BM (elutriation and Isolex, 500,000 CD3/kg).
PBSC recipients received no GVHD prophylaxis; BM recipients
received CyA only. The median age was 6 years (range 5 to 15
years); 5 were males; 3 had a 5/6 match. 8/10 are alive, fully
engrafted with normal blood counts with follow-up of 1-29
months (median 7 months). The median day to ANC>500 was 10
days (range 8-14 days); to platelet independence 20 days (range
17-71 days). 3/5 BM recipients developed grade III GVHD; one
of these died of Aspergillus pneumonia with cGVHD 9 months
after BMT. One of the two BM recipients who did not develop
GVHD died on day +39 of pulmonary failure and ARDS of
unknown etiology, though infection was clinically suspected. All 5
PBSC recipients rapidly engrafted without GVHD and are alive
and well. In conclusion, though follow-up is short, this regimen
has resulted in full engraftment in all patients with a low risk for
organ toxicity. GVHD has only been seen in partially-TCD BM
recipients and overall 8/10 patients survive. This study is being
modiﬁed to more thoroughly TCD the BM recipient marrows.
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CORRECTION OF KRABBE DISEASE WITH NEONATAL HEMATOPOIET-
IC STEM CELL TRANSPLANTATION
Kurtzberg, J.1; Richards, K.2; Wenger, D.3; Provenzale, J.1;
Escolar, M.L.1; Wall, D.4; Champagne, M.A.5; Krivit, W.6 1. Duke
University Medical Center, Durham, NC; 2. San Antonio Military
Pediatric Center, San Antonio, TX; 3. Jefferson Medical College,
Philadelphia, PA; 4. Texas Transplant Institute, San Antonio, TX;
5. Universite de Montreal by Hopital Sainte-Justine, Montreal, ON,
Canada; 6. University of Minnesota, Minneapolis, MN
Globoid cell leukodystrophy is caused by a deﬁciency of galacto-
cerebrosidase resulting in accumulation of psychosine which is
toxic to the brain. When this occurs in the infantile form (Krabbe
disease, KD), loss of central nervous system function is rapid and
death occurs before 2 years of age. We now report outcomes of 6
infants with KD transplanted (5 with unrelated umbilical cord
blood [UCB] and 1 with matched sibling bone marrow) after
preparation with high dose chemotherapy in the neonatal period.
All patients had a previous sibling who had died from KD leading
to early diagnosis and treatment. In the 5 patients lacking a related
donor, unrelated UCB donors were selected. All babies survived
the transplant and engrafted neutrophils within 4 weeks and
platelets within 8 weeks of transplant. All achieved 100% donor
chimerism before 100 days post transplant. The 5/6 recipients of
unrelated UCB remain full donor chimeras from 1-4 years post
transplant. The 1 patient who received HLA-matched sibling
bone marrow is a mixed chimera (75% donor, 25% host) 5 years
post transplant. With a median follow-up of >2.5 years, all
patients have survived well beyond their affected siblings and all
have experienced remarkably positive clinical courses, gaining
normal milestones, development and growth post transplant. In all
cases, MRI demonstrated increased myelination and nerve con-
duction velocities improved over time. We conclude that neonatal
transplantation for KD produces excellent results. The use of
UCB donors for patients lacking related donors facilitates therapy
98
Poster Presentations - Session I
shortly after birth. In contrast, the use of stem cell transplantation
in patients without a family history who were symptomatic at >3
months after birth, fails to produce positive results. Planning is
now underway for identifying non-familial cases by neonatal
screening as well as for selection of donors with high levels of
endogenous enzyme.
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SIBLING DONOR CORD BLOOD (SDCB) BANKING AND TRANSPLAN-
TATION FOR CHILDREN WITH SICKLE CELL ANEMIA (SCA) AND THA-
LASSEMIA (TH): CHILDREN’S HOSPITAL OAKLAND SIBLING DONOR
CORD BLOOD PROGRAM
Lubin, B.H.1; Reed, W.1; Smith, R.1; Dekovic, F.1; Lee, J.Y.3;
Saba, J.D.1; Trachtenberg, E.1; Walters, M.C.2 1. Children’s Hospital
Oakland Research Institute, Oakland, CA; 2. Children’s Hospital Oak-
land, Oakland, CA; 3. Alta Bates Summit Medical Center, Berkeley, CA
SCA and TH can be cured by an HLA matched related
hematopoetic stem cell (HSC) transplantation. Although engraft-
ment concerns have been raised, sibling donor cord blood may be
an ideal source of HSCs for this purpose. We developed a national
program to collect SDCB. We have collected over 175 CB sam-
ples in 42 states. CB was collected following a specific protocol
and transported overnight to our laboratory. Molecular HLA typ-
ing was performed on the CB and potential recipient. Nucleated
cell count, CD34 number, viability, proliferative assays, screening
for pathogens and hemoglobin diagnostic studies were done on
each unit. Collections primarily occurred at community hospitals.
A low bacterial contamination rate (less than 1%) was noted. The
volume and nucleated cell count in each SDCB provided over
2.5x107 cells/kg recipient weight in 85% of the cases. Seven HLA
matched CBs were utilized for transplantation of a sibling who
had SCA or TH. Transplant protocols were not standardized. All
SDCB transplants engrafted. None of the children demonstrated
evidence of disease 24 months post transplantation and none of
the transplanted patients had signiﬁcant GVHD. Taken together
with recent results reported by NETCORD (Locatelli et al, 2000),
44 children with hemoglobinopathies (33 thalassemia, 11 sickle
cell anemia) have been transplanted with HLA matched SDCB
worldwide and 85% appear to have been cured. The remaining
children failed to engraft. None died as a result of the transplant.
These results suggest that cord blood collection should be encour-
aged in families who currently have a child with a hemoglobinopa-
thy. A national program supporting this effort should be devel-
oped. Modiﬁcation of the conditioning regimen and provision of a
critical cell dose in the transplant protocol may enhance engraft-
ment and provide additional support for the consideration of CB
transplantation as a treatment option in children with SCA or TH.
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STEM CELL TRANSPLANTATION FOR PATIENTS WITH X-LINKED
THROMBOCYTOPENIA
Nonoyama, S. Tokyo Medical and Dental University, Bunkyo-ku, Japan
Wiskott-Aldrich syndrome (WAS) is an X-linked recessive
genetic disorder characterized by severe eczema, thrombocytope-
nia and immunodeﬁciency. Following the identiﬁcation of WASP
as the responsible gene for WAS, X-linked thrombocytopenia
(XLT) has been found to be caused by the same gene defect,
although displaying only thrombocytopenia. Due to the high mor-
tality rates stem cell transplantation (SCT) is necessary to treat
WAS patients, however the necessity of SCT for XLT patients
presently remains unclear. The prognosis of 27 XLT patients in
Japan was investigated. All patients had decreased platelet counts,
WASP gene mutations and showed defective WASP protein
expression, as was confirmed by western blot hybridization or
flowcytometry. Intracranial hemorrhage occurred in 6 of 27
patients (22%), which is more than 20 times higher than that
reported for chronic ITP patients. IgA nephropathy was observed
in five patients, and in two of them renal failure rapidly pro-
gressed, with blood dialysis being required for both patients with-
in 6 months of the onset of IgA nephropathy. Two patients suf-
fered myelodysplastic syndrome. These observations
demonstrated that the long-term prognosis of XLT is not good as
has previously been considered, due to their severe complications.
Based on these ﬁndings, ﬁve XLT patients were treated with stem
cell transplantation (one cord blood stem cell transplantation, four
bone marrow transplantation from siblings (three cases) or unre-
lated donor (one case)). BU+CY was used as the conditioning reg-
imen for all patients. In all patients, engraftments were achieved,
and their platelet numbers increased to a normal range, WASP
mutations and protein expression became normalized. A single
patient with IgA nephropathy was cured following the SCT. From
these results, it is proposed that SCT for XLT patients should be
considered as a choice of curative therapy.
133
CORRECTION OF HURLER SYNDROME WITH UNRELATED UMBILICAL
CORD BLOOD TRANSPLANTATION
Staba, S.; Martin, P.L.; Szabolcs, P.; Driscoll, T.; Allison-Thacker, J.;
Wood, S.; Escolar, M.L.; Kurtzberg, J. Duke University Medical Cen-
ter, Durham, NC
Hurler syndrome (HS) is caused by genetic deﬁciency of alpha-
L-iduronidase resulting in progressive central nervous system
deterioration, atherosclerotic heart disease, boney deformities and
death in childhood. Bone marrow transplantation (BMT) before 2
years of age stops disease progression and prolongs life but many
children in need of a BMT lack an appropriate donor. Umbilical
cord blood (UCB) provides a readily available source of
hematopoietic stem cells for transplantation of these patients.
Most BMT protocols employ total body irradiation (TBI) as part
of the preparative regimen. We reasoned that TBI in children <2
years of age would increase the risk of CNS injury and developed
a chemotherapy-based regimen (busulfan, cyclophosphamide,
ATG) which we tested in 14 consecutive patients with HS trans-
planted with unrelated UCB between 12/95 and 8/01. The medi-
an patient age was 16 months (range 3 mo – 2.5 yrs). The degree
of HLA mismatch between donor and recipient varied: one 3/6,
three 4/6 and ten 5/6 matches. Cell dose ranged from 1.91 to
20.95 x 10e7 cells/kg (median 8.38 x 10e7 cells/kg). All evaluable
patients (n=13) successfully engrafted achieving an ANC >500 in a
median of 24 days (range 10-39 days) and maintain >99% donor
chimerism. Five children experienced grade I acute GVHD, 3 had
grade II and 1 had grade III. No children developed chronic
GVHD. Signiﬁcant but reversible post transplant events included
pulmonary hemorrhage (n=1), autoimmune hemolytic anemia
(n=1) and VP shunt infection (n=2). Twelve of the 14 children are
surviving event-free for a median of 829 days (range 100-2159
days. Two children died, one from hyperammonemia 30 days
post-transplant and one from a hemmorrhagic stroke 90 days
post-transplant. We conclude that UCB is an excellent and readily
available stem cell source for allogeneic BMT for HS. Durable
engraftment can be achieved without TBI. ααα
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FAMILIAL DYSHEMATOPOIESIS SUCCESSFULLY TREATED WITH
ALLOGENEIC BONE MARROW
Stein, J.1; Yaniv, I.1; Tamary, H.1; Shalev, H.2; Kapelushnik, J.2;
Resnitzky, P.3 1. Schneider Children’s Medical Center of Israel, Petach
Tikva, Israel; 2. Soroka Medical Center, Beer Sheva, Israel; 3. Efrati
Research Institute for Blood Cells, Kaplan Hospital, Rehovot, Israel
Three female members of a large, inbred kindred presented at
birth with congenital pancytopenia (severe thrombocytopenia,
moderate anemia and neutropenia). All three of the patients had
experienced intracerebral hemorrhages before referral to our cen-
ter. Red blood cell survival was decreased and platelet responses to
ADP and thrombin were markedly impaired. Bone marrow exami-
nation revealed hypercellularity and electron-microscopic changes
consistent with dysmyelopoiesis, dyserythropoiesis and abnormal
megakaryocyte maturation. In-vitro assessment of megakaryocyte
colony formation showed severely impaired megakaryocyte devel-
opment. All three patients underwent allogeneic bone marrow
transplantation (at ages 22 months, 45 months, and 8 years) from
HLA identical siblings. Conditioning consisted of oral busulfan
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(600mg/m2 in two patients and targeted therapy in the third -
AUC 1100), cyclophosphamide 200 mg/kg, and anti-thymocyte
globulin (Fresenius) 80 mg/kg, each over four days. GVHD pro-
phylaxis consisted of short-course methotrexate and cyclosporin
A. One patient developed mild veno-occlusive disease, and one
patient developed mild gastrointestinal toxicity. ANC of >500/ul
was achieved on day +18 in two patients and on day +21 in the
third, while a platelet count of >20,000/ul was attained at day +22
in two patients and at day +25 in the third. Full hematopoietic
chimerism and resolution of cytopenias and platelet abnormalities
were documented in these patients, who are thriving 3, 37 and 51
months after transplant. This unusual familial syndrome respond-
ed well to bone marrow transplantation, suggesting a inherited
stem cell defect in these patients.
